<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        3011200301
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Rivaroxaban SPC
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        RIVAROXABAN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        179.60
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="DR. REDDY" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            DR. REDDY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2272]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SUDAIR PHARMA COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SUDAIR PHARMA COMPANY
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        B01AF01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Rivaroxaban SPC contains the active substance Rivaroxaban.</p><p>Rivaroxaban SPC is used in adults to:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; prevent blood clots in brain (stroke) and other blood vessels in your body if you have a form of irregular heart rhythm called non-valvular atrial fibrillation.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; treat blood clots in the veins of your legs (deep vein thrombosis) and in the blood vessels of your lungs (pulmonary embolism), and to prevent blood clots from re-occurring in the blood vessels of your legs and/or lungs.</p><p>&nbsp;</p><p>Rivaroxaban SPC is used in children and adolescents below 18 years and with a body weight of 30 kg or&nbsp;more to:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; treat blood clots and prevent re-occurrence of blood clots in the veins or in the blood vessels of&nbsp;the lungs, following initial treatment of at least 5 days with injectable medicines used to treat&nbsp;blood clots.</p><p>&nbsp;</p><p>Rivaroxaban SPC belongs to a group of medicines called antithrombotic agents. It works by blocking a blood clotting factor (factor Xa) and thus reducing the tendency of the blood to form clots.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take Rivaroxaban SPC</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>if you are allergic </strong>to Rivaroxaban SPC or any of the other ingredients of this medicine (listed in section 6)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are bleeding excessively</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>if you have a disease or condition in an organ of the body that increases the risk of serious bleeding (e.g. stomach ulcer, injury or bleeding in the brain, recent surgery of the brain or eyes)</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking medicines to prevent blood clotting (e.g. warfarin, dabigatran, apixaban or heparin), except when changing anticoagulant treatment or while getting heparin through a venous or arterial line to keep it open.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>if you have a liver disease </strong>which leads to an increased risk of bleeding</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are pregnant or breast-feeding</p><p>&nbsp;</p><p><strong>Do not take Rivaroxaban SPC and tell your doctor if any of these apply to you. Warnings and precautions</strong></p><p>Talk to your doctor or pharmacist before taking Rivaroxaban SPC.</p><p>&nbsp;</p><p>Take special care with Rivaroxaban SPC</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have <strong>an increased risk of bleeding, as could be the case in situations </strong>such as:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>moderate or severe kidney disease</strong>, since your kidney function may affect the amount of medicine that works in your body</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking other medicines to prevent blood clotting (e.g. warfarin, dabigatran, apixaban or heparin), when changing anticoagulant treatment or while getting heparin through a venous or arterial line to keep it open (see section &ldquo;Other medicines and Rivaroxaban SPC&rdquo;)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding disorders</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>very high blood pressure</strong>, not controlled by medical treatment</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diseases of your stomach or bowel that might result in bleeding, e.g. inflammation of the bowels or stomach, or inflammation of the oesophagus (gullet), e.g. due to gastroesophageal reflux disease (disease where stomach acid goes upwards into the oesophagus)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a problem with the blood vessels in the back of your eyes (retinopathy)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a lung disease where your bronchi are widened and filled with pus (bronchiectasis), or previous bleeding from your lung</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a prosthetic heart valve</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you know that you have a disease called antiphospholipid syndrome (a disorder of the immune system that causes an increased risk of blood clots), tell your doctor who will decide if the treatment may need to be changed.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if your doctor determines that your blood pressure is unstable or another treatment or surgical procedure to remove the blood clot from your lungs is planned</p><p><strong>If any of the above apply to you, tell your doctor </strong>before you take Rivaroxaban SPC. Your doctor will decide, if you should be treated with this medicine and if you should be kept under closer observation.</p><p>If you need to have an operation</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; it is very important to take Rivaroxaban SPC before and after the operation exactly at the times you have been told by your doctor.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your operation involves a catheter or injection into your spinal column (e.g. for epidural or spinal anaesthesia or pain reduction):</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; it is very important to take Rivaroxaban SPC before and after the injection or removal&nbsp;&nbsp;of the catheter exactly at the times you have been told by your doctor</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tell your doctor immediately if you get numbness or weakness of your legs or problems with your bowel or bladder after the end of anaesthesia, because urgent care is necessary</p><p><strong>&nbsp;Children and adolescents</strong></p><p>&nbsp;Rivaroxaban SPC 15 mg, 20 mg tablets are not recommended for children with a body weight below 30 kg.</p><p>&nbsp;There is not enough information on the use of Rivaroxaban SPC 15 mg, 20 mg tablets in children and adolescents in the adult indications.</p><p>&nbsp;</p><p><strong>Other medicines and Rivaroxaban SPC</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are taking</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some medicines for fungal infections (e.g. fluconazole, itraconazole, voriconazole, posaconazole), unless they are only applied to the skin</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ketoconazole tablets (used to treat Cushing&rsquo;s syndrome - when the body produces an excess of cortisol)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some medicines for bacterial infections (e.g. clarithromycin, erythromycin)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some anti-viral medicines for HIV / AIDS (e.g. ritonavir)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; other medicines to reduce blood clotting (e.g. enoxaparin, clopidogrel or vitamin K antagonists such as warfarin and acenocoumarol)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anti-inflammatory and pain relieving medicines (e.g. naproxen or acetylsalicylic acid)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dronedarone, a medicine to treat abnormal heart beat</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some medicines to treat depression (selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs))</p><p><strong>If any of the above apply to you, tell your doctor </strong>before taking Rivaroxaban SPC, because the effect of Rivaroxaban SPC may be increased. Your doctor will decide, if you should be treated with this medicine and if you should be kept under closer observation.</p><p>If your doctor thinks that you are at increased risk of developing stomach or bowel ulcers, he may also use a preventative ulcer treatment.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are taking</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some medicines for treatment of epilepsy (phenytoin, carbamazepine, phenobarbital)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; St John&rsquo;s Wort (Hypericum perforatum), a herbal product used for depression</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rifampicin, an antibiotic</p><p><strong>If any of the above apply to you, tell your doctor </strong>before taking Rivaroxaban SPC, because the effect of Rivaroxaban SPC may be reduced. Your doctor will decide, if you should be treated with Rivaroxaban SPC and if you should be kept under closer observation</p><p><strong>Pregnancy and breast-feeding</strong></p><p>Do not take Rivaroxaban SPC <strong>if you are pregnant or breast-feeding</strong>. If there is a chance that you could become pregnant, use a reliable contraceptive while you are taking Rivaroxaban SPC. If you become pregnant while you are taking this medicine, tell your doctor immediately, who will decide how you should be treated.</p><p><strong>Driving and using machines</strong></p><p>Rivaroxaban SPC may cause dizziness (common side effect) or fainting (uncommon side effect) (see section 4 &ldquo;Possible side effects&rdquo;). You should not drive, ride a bicycle or use any tools or machines if you are affected by these symptoms.</p><p><strong>Rivaroxaban SPC contains lactose and sodium</strong></p><p>If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine. This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially &ldquo;sodium-free&rdquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist &nbsp;if you are not sure.</p><p>&nbsp;You must take Rivaroxaban 15 mg, 20 mg tablets&nbsp;together with a meal.</p><p>Swallow the tablet(s) preferably with water.</p><p>If you have difficulty swallowing the tablet whole, talk to your doctor about other ways to take Rivaroxaban SPC. The tablet may be crushed and mixed with water or apple puree immediately before you take it. This mixture should be immediately followed by food.</p><p>If necessary, your doctor may also give you the crushed Rivaroxaban SPC tablet through a stomach tube.</p><p>&nbsp;</p><p><strong>How much to take</strong></p><p>&nbsp;</p><p><strong>Adults </strong></p><p><strong>&nbsp;</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; To prevent blood clots in brain (stroke) and other blood vessels in your body The recommended dose is one tablet Rivaroxaban SPC 20 mg once a day.</p><p>If you have kidney problems, the dose may be reduced to one tablet Rivaroxaban SPC 15 mg once a day.</p><p>If you need a procedure to treat blocked blood vessels in your heart (called a percutaneous coronary intervention - PCI with an insertion of a stent), there is limited evidence to reduce the dose to one tablet Rivaroxaban SPC 15 mg once a day (or to one tablet Rivaroxaban SPC 10 mg once a day in case your kidneys are not working properly) in addition to an antiplatelet medicinal product such as clopidogrel..</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; To treat blood clots in the veins of your legs and blood clots in the blood vessels of your lungs, and for preventing blood clots from re-occurring, the recommended dose is one tablet Rivaroxaban SPC 15 mg twice a day for the first 3 weeks. For treatment after 3 weeks, the recommended dose is one tablet Rivaroxaban SPC 20 mg once a day. After at least 6 months blood clot treatment your doctor may decide to continue treatment with either one 10 mg tablet once a day or one 20 mg tablet once a day.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have kidney problems and take one tablet Rivaroxaban SPC 20 mg once a day, your doctor may decide to reduce the dose for the treatment after 3 weeks to one tablet Rivaroxaban SPC 15 mg once a day if the risk for bleeding is greater than the risk for having another blood clot.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>The dose of Rivaroxaban SPC depends on the body weight, and will be calculated by the doctor.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The recommended dose for children and adolescents with a body weight between 30 kg and&nbsp;less than 50 kg is one Rivaroxaban SPC 15 mg tablet once a day.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The recommended dose for children and adolescents with a body weight of 50 kg or more is&nbsp;one Rivaroxaban SPC 20 mg tablet once a day.</p><p>&nbsp;</p><p>Take each Rivaroxaban SPC dose with a drink (e.g. water or juice) during a meal. Take the tablets every day at&nbsp;approximately the same time. Consider setting an alarm to remind you.</p><p>For parents or caregivers: please observe the child to ensure the full dose is taken.</p><p>As the Rivaroxaban SPC dose is based on body weight it is important to keep scheduled doctor&rsquo;s visits because&nbsp;the dose may need to be adjusted as the weight changes.</p><p>&nbsp;</p><p><strong>Never adjust the dose of </strong>Rivaroxaban SPC <strong>by yourself. </strong>The doctor will adjust the dose if necessary.</p><p>Do not split the tablet in an attempt to provide a fraction of a tablet dose.</p><p>For children and adolescents who are unable to swallow tablets whole or if a lower dose is required, you may&nbsp;crush the Rivaroxaban SPC tablet and mix with water or apple puree immediately before taking. Take some food after taking this mixture. If necessary, your doctor may also give the crushed Rivaroxaban SPC tablet&nbsp;through a stomach tube.</p><p>&nbsp;</p><p><strong>If you spit up the dose or vomit</strong></p><p>-&nbsp; &nbsp; &nbsp;less than 30 minutes after you have taken Rivaroxaban&nbsp;SPC , take a new dose.</p><p>-&nbsp; &nbsp; &nbsp;more than 30 minutes after you have taken Rivaroxaban&nbsp;SPC, do not take a new dose. In this case, take the next Rivaroxaban&nbsp;SPC dose at the usual time.</p><p>Contact the doctor if you repeatedly spit up the dose or vomit after taking Rivaroxaban&nbsp;SPC.</p><p>&nbsp;</p><p><strong>When to take Rivaroxaban SPC</strong></p><p>&nbsp;</p><p>Take the tablet(s) every day until your doctor tells you to stop.</p><p>Try to take the tablet(s) at the same time every day to help you to remember it. Your doctor will decide how long you must continue treatment.</p><p>To prevent blood clots in the brain (stroke) and other blood vessels in your body: If your heart beat needs to be restored to normal by a procedure called cardioversion, take Rivaroxaban SPC at the times your doctor tells you.</p><p>&nbsp;</p><p><strong>If you take more Rivaroxaban SPC than you should</strong></p><p><strong>Contact your doctor immediately </strong>if you have taken too many Rivaroxaban SPC tablets. Taking too much Rivaroxaban SPC increases the risk of bleeding.</p><p>&nbsp;</p><p><strong>If you forget to take Rivaroxaban SPC</strong></p><p>&nbsp;Adults, children and adolescents:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are taking one 20 mg tablet or one 15 mg tablet once a day and have missed a dose, take it as soon as you remember. Do not take more than one tablet in a single day to make up for a forgotten dose. Take the next tablet on the following day and then carry on taking one tablet once a day.</p><p>&nbsp;Adults:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are taking one 15 mg tablet twice a day and have missed a dose, take it as soon as you remember. Do not take more than two 15 mg tablets in a single day. If you forget to take a dose you can take two 15 mg tablets at the same time to get a total of two tablets (30 mg) on one day. On the following day you should carry on taking one 15 mg tablet twice a day.</p><p><strong>If you stop taking Rivaroxaban SPC</strong></p><p>Do not stop taking Rivaroxaban SPC without talking to your doctor first, because Rivaroxaban SPC treats and prevents serious conditions.</p><p>If you have any further questions on the use of this medicine, ask your doctor or health care provider</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Rivaroxaban SPC can cause side effects, although not everybody gets them.</p><p>Like other similar medicines (antithrombotic agents), Rivaroxaban SPC may cause bleeding which may potentially be life threatening. Excessive bleeding may lead to a sudden drop in blood pressure (shock). In some cases the bleeding may not be obvious.</p><p>Possible side effects which may be a sign of bleeding</p><p><strong>Tell your doctor immediately if you or child experience any of the following side effects:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;bleeding into the brain or inside the skull (symptoms can include headache, one-sided weakness,&nbsp;vomiting, seizures, decreased level of consciousness, and neck stiffness. A serious medical&nbsp;emergency. Seek medical attention immediately!)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; long or excessive bleeding</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; exceptional weakness, tiredness, paleness, dizziness, headache, unexplained swelling, breathlessness, chest pain or angina pectoris, which may be signs of bleeding.</p><p>Your doctor may decide to keep you under closer observation or change how you should be treated.</p><p><strong>Possible side effects which may be a sign of severe skin reaction</strong></p><p>Tell your doctor immediately if you experience skin reactions such as:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; spreading intense skin rash, blisters or mucosal lesions, e.g. in the mouth or eyes (StevensJohnson syndrome/toxic epidermal necrolysis). The frequency of this side effect is very rare (up to 1 in 10,000).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a drug reaction that causes rash, fever, inflammation of internal organs, hematologic abnormalities and systemic illness (DRESS syndrome). The frequency of this side effect is very rare (up to 1 in 10,000).</p><p><strong>Possible side effects which may be a sign of severe allergic reactions</strong></p><p>Tell your doctor immediately if you experience any of the following side effects:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of the face, lips, mouth, tongue or throat; difficulty swallowing; hives and breathing difficulties; sudden drop in blood pressure. The frequencies of these side effects are very rare (anaphylactic reactions, including anaphylactic shock; may affect up to 1 in 10,000 people) and uncommon (angioedema and allergic oedema; may affect up to 1 in 100 people).</p><p><strong>Overall list of possible side effects found in adults, children and adolescents &nbsp;Common (may affect up to 1 in 10 people)</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduction in red blood cells which can make the skin pale and cause weakness or breathlessness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding in the stomach or bowel, urogenital bleeding (including blood in the urine and heavy menstrual bleeding), nose bleed, bleeding in the gum</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding into the eye (including bleeding from the whites of the eyes)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding into tissue or a cavity of the body (haematoma, bruising)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; coughing up blood</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding from the skin or under the skin</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding following an operation</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; oozing of blood or fluid from surgical wound</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling in the limbs</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain in the limbs</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; impaired function of the kidneys (may be seen in tests performed by your doctor)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach ache, indigestion, feeling or being sick, constipation, diarrhoea</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood pressure (symptoms may be feeling dizzy or fainting when standing up)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased general strength and energy (weakness, tiredness), headache, dizziness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash, itchy skin</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood tests may show an increase in some liver enzymes</p><p>&nbsp;</p><p><strong>Uncommon (may affect up to 1 in 100 people)</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding into the brain or inside the skull</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding into a joint causing pain and swelling</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; thrombocytopenia (low number of platelets, which are cells that help blood to clot)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic reactions, including allergic skin reactions</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; impaired function of the liver (may be seen in tests performed by your doctor)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood tests may show an increase in bilirubin, some pancreatic or liver enzymes or in the number of platelets</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fainting</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling unwell</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; faster heartbeat</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dry mouth</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hives</p><p><strong>Rare (may affect up to 1 in 1,000 people)</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding into a muscle</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cholestasis (decreased bile flow), hepatitis incl. hepatocellular injury (inflamed liver incl. liver injury)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; yellowing of the skin and eye (jaundice)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; localised swelling</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; collection of blood (haematoma) in the groin as a complication of the cardiac procedure where a catheter is inserted in your leg artery (pseudoaneurysm)</p><p><strong>Not known (frequency cannot be estimated from the available data)</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; kidney failure after a severe bleeding</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased pressure within muscles of the legs or arms after a bleeding, which leads to pain, swelling, altered sensation, numbness or paralysis (compartment syndrome after a bleeding)</p><p>&nbsp;</p><p><strong>&nbsp;Side effects in children and adolescents</strong></p><p>In general, the side effects observed in children and adolescents treated with Xarelto were similar in&nbsp;type to those observed in adults and were primarily mild to moderate in severity<br /><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1025" type="#_x0000_t75" style='width:445.4pt;height:27.5pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>Side effects that were observed more often in children and adolescents:</p><p><strong>Very common (may affect more than 1 in 10 people)</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;headache</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;fever</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;nose bleeding</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;vomiting</p><p><strong>Common (may affect up to 1 in 10 people)</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp; raised heartbeat.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; blood tests may show an increase in bilirubin (bile pigment)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; thrombocytopenia (low number of platelets which are cells that help blood to clot)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; heavy menstrual bleeding</p><p>&nbsp;</p><p><strong>Uncommon (may affect up to 1 in 100 people)</strong></p><p>-&nbsp; &nbsp; &nbsp;blood tests may show an increase in a subcategory of bilirubin (direct bilirubin, bile pigment)</p><p>&nbsp;</p><p>Reporting of side effects</p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell&nbsp;your &lt;doctor, health care provider&gt; &lt;or&gt; &lt;pharmacist&gt;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Store below 30&deg;C</p><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the carton and on each blister or bottle after EXP.</p><p>The expiry date refers to the last day of that month.</p><p>This medicine does not require any special storage conditions.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>The active substance </strong>is Rivaroxaban. Each tablet contains 15 mg or 20 mg of Rivaroxaban.</p><p><strong>Other ingredients </strong>are Microcrystalline cellulose, Croscarmellose sodium, Lactose monohydrate, Hypromellose 5 CPS, Sodium lauryl sulphate, Magnesium stearate, Opadry 04F540025 Pink, Opadry brown 04F565014, Opadry red 04F550002.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Rivaroxaban SPC 15 mg tablets
Red colored, round biconvex film coated tablet (Diameter: Approximately 6 mm), engraved with ‘15’ on one side and plain on the other side.

Rivaroxaban SPC 20 mg tablets
Dark red colored, round biconvex film coated tablet (Diameter: Approximately 6 mm), engraved with ‘20’ on one side and plain on the other side.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>MARKETING AUTHORIZATION HOLDER:</strong></p><p>Sudair Pharma Company (SPC) King Fahad road, Building no.8006,</p><p>Riyadh 4432, Saudi Arabia Tel: +966-11-920001432</p><p>Fax: +966-11-4622230</p><p>Email: info@sudairpharma.com</p><p>Mailing: P.O. Box 12363 Riyadh, Saudi Arabia</p><p>&nbsp;</p><p><strong>Manufacturer:</strong></p><p>&nbsp;Dr. Reddy&rsquo;s Laboratories Limited,</p><p>&nbsp;FTO-Unit 2 Survey No. 42, 45 &amp;</p><p>&nbsp;46, Bachupally Village,</p><p>&nbsp;Qutubullapur Mandal,</p><p>&nbsp;Ranga Reddy District,</p><p>&nbsp;Telangana, IND &ndash; 500 090,</p><p>&nbsp;India</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                 This leaflet was last revised in 02/2021  
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي دواء ريفاروكسابان إس بي سي على المادة الفعاّلة ريفاروكسابان.</p><p dir="RTL">يسُتخدم دواء ريفاروكسابان إس بي سي في المرضى من البالغين لعلاج الحالات التالية:</p><p dir="RTL">- لمنع تكوُّن الجلطات الدموية في المخ (السكتة الدماغية) وفي الأوعية الدموية الأخرى بالجسم إذا كان تعاني من أحد أشكال عدم انتظام ضربات القلب الذي يسمى الرجفان الأذيني غير الصمامي.</p><p dir="RTL">- لعلاج الجلطات الدموية في أوردة الساقين (التجلط الوريدي العميق) وفي الأوعية الدموية بالرئتين (الانصمام الرئوي) ، ولمنع تكرار الإصابة بالجلطات الدموية في الأوعية الدموية بالساقين و/أو الرئتين.</p><p dir="RTL">يسُتخدم دواء ريفاروكسابان إس بي سي في المرضى من الأطفال والمراھقین تحت سن 18 عاماً ووزن قدره 30 كجم أو أكثر لعلاج الحالات التالية:</p><p dir="RTL">- لعلاج الجلطات الدموية ولمنع تكرار الإصابة بالجلطات الدموية في الأوردة أو في الأوعية الدموية بالرئتين، بعد علاج أولي لمدة 5 أيام على الأقل عن طريق أدوية عن طريق الحقن تستخدم لعلاج الجلطات الدموية.</p><p dir="RTL">ينتمي دواء ريفاروكسابان إس بي سي إلى مجموعة من الأدوية تعرف باسم الأدوية المانعة لتجلط الدم.</p><p dir="RTL">يعمل هذا الدواء على إيقاف تأثير عوامل تجلط الدم (العامل العاشر)، وبالتالي ينخفض معدل تكون الجلطات في الدم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>يحضر عليك تناول دواء ريفاروكسابان إس بي سي في الحالات التالية</strong><strong>:</strong></p><p dir="RTL">- إذا كنت تعاني من حساسية تجاه دواء ريفاروكسابان إس بي سي أو تجاه أي مكون من المكونات الأخرى الداخلة بتركيب هذا الدوَّاء (المدرجة في القسم رقم: 6).</p><p dir="RTL"><strong>- </strong><strong>إذا كنت تعاني من نزيف شديد ومستمر.</strong></p><p dir="RTL"><strong>- </strong><strong>إذا كنت تعاني من مرض أو اضطراب بأحد أعضاء الجسم تزيد من معدل خطر التعرض لنزيف شديد (على سبيل المثال قرحة المعدة أو إصابة أو نزيف في الدماغ والخضوع لجراحة حديثة بالمخ أو بالعينين).</strong></p><p dir="RTL">- إذا كنت تتناول أدوية لمنع تجلط الدم (على سبيل المثال؛ وارفارين أو دابيجاتران أو أبيكسابان أو هيبارين) ، إلا في حالة تغيير العلاج المضاد للتجلط أو من خلال استخدام هيبارين عن طريق أنبوب الحقن بالتنقيط داخل الوريد أو الشريان لإبقائه مفتوحًا (منع انسداده).</p><p dir="RTL">- <strong>إذا كنت تعاني من مرض في الكبد </strong>يؤدي إلى زيادة خطر التعرض للنزيف.</p><p dir="RTL"><strong>- </strong><strong>إذا كنتِ حاملاً أو تمارسين الرضاعة الطبيعية.</strong></p><p dir="RTL"><strong>يحضر عليك تناول دواء ريفاروكسابان إس بي سي وأخبر الطبيب المعالج لك، إذا انطبق عليك أيٌّ مما سبق.</strong></p><p dir="RTL"><strong>تحذيرات واحتياطات</strong><strong>:</strong></p><p dir="RTL">استشر الطبيب المعالج لك أو الصيدلي الخاص بك قبل تناول دواء ريفاروكسابان إس بي سي.</p><p dir="RTL"><strong>توخ حذرًا خاصًا عند تناول دواء ريفاروكسابان إس بي سي في الحالات التالية</strong><strong>:</strong></p><p dir="RTL">- إذا كنت تعاني <strong>من زيادة خطر التعرض للإصابة بالنزيف، على سبيل المثال الحالات التالية</strong><strong>:</strong></p><p dir="RTL">&bull; إذا كنت تعاني من <strong>أمراض متوسطة أو شديدة بالكلى، </strong>حيث يمكن أن تؤثر وظائف الكلى على كمية الدواء الممتصة داخل الجسم.</p><p dir="RTL">&bull; إذا كنت تتناول أدوية أخرى لمنع تجلط الدم (مثل؛ وارفارين أو دابيجاتران أو أبيكسابان أو هيبارين) ، عندما يتم تغيير العلاج المانع لتجلط الدم أو من خلال استخدام هيبارين عن طريق الحقن بالتنقيط داخل الوريد أو الشريان لإبقائه مفتوحًا (منع انسداده) (انظر قسم &quot; تناوُل دواء ريفاروكسابان إس بي سي مع أدوية أخرى&quot;).</p><p dir="RTL"><strong>&bull; </strong>إذا كنت تعاني من <strong>اضطرابات بنزيف الدم.</strong></p><p dir="RTL">&bull; إذا كنت تعاني من ارتفاع ضغط الدم، الغير مسيطر عليه بالعلاج الدوائي.</p><p dir="RTL">&bull; إذا كنت تعاني من أمراض المعدة أو الأمعاء التي قد تؤدي إلى نزيف، على سبيل المثال التهاب الامعاء أو المعدة أو التهاب المريء، على سبيل المثال بسبب الارتجاع المعدي المريئي (يحدث هذا المرض عندما يتدفق حمض المعدة صاعداً إلى المريء).</p><p dir="RTL">&bull; إذا كنت تعاني من <strong>اضطرابات بالأوعية الدموية الموجودة في الجزء الخلفي من العين </strong>(اعتلال الشبكية).</p><p dir="RTL">&bull; إذا كنت تعاني من أمراض الرئة، حيث تتمدد الشُعب الهوائية الخاصة بك وتمتلئ بالصديد (توسع الشُعب الهوائية) أو الإصابة مسٌبقاً بنزيف من الرئتين.</p><p dir="RTL">- إذا خضعت لزراعة صمام قلب اصطناعي.</p><p dir="RTL">- إذا كنت على معرفة بأنك مصاب بمرض يسمى متلازمة الأجسام المضادة للفوسفولبيد (وهو عبارة عن وجود اضطراب في الجهاز المناعي يؤدي إلى تفاقم مخاطر تكون تجلطات في الدم) ، أخبر الطبيب المعالج لك الذي بدوره سيقرر ما إذا كان العلاج يحتاج إلى تغيير أم لا.</p><p dir="RTL">- إذا أبلغك الطبيب المعالج لك بأن ضغط الدم لديك غير مستقر أو أنه من المخطط تلقي علاج أو إجراء جراحي آخر لإزالة الجلطة الدموية من الرئتين.</p><p dir="RTL"><strong>أخبر الطبيب المعالج لك، إذا انطبقت عليك أي حالة من الحالات السابقة</strong>، قبل تناول دواء ريفاروكسابان إس بي سي<strong>. </strong>سيقرر الطبيب المعالج ما إذا كان يجب علاجك باستخدام دواء ريفاروكسابان إس بي سي وما إذا كان يتوجب متابعة حالتك الصحية عن قرب.</p><p dir="RTL"><strong>إذا كنت بحاجة إلى إجراء عملية جراحية</strong><strong>:</strong></p><p dir="RTL">- من المهم جداً تناول دواء ريفاروكسابان إس بي سي قبل الخضوع إلى إجراء عملية جراحية وبعدها في المواعيد التي أخبرك بها الطبيب المعالج لك تمامًا.</p><p dir="RTL">- إذا كانت العملية الجراحية تستلزم إجراء قسطرة أو حقن في العمود الفقري (على سبيل المثال، للتخدير فوق الجافية أو النخاع الشوكي أو حقن لتقليل الألم):</p><p dir="RTL">&bull; من المهم جدا أن تتناول دواء ريفاروكسابان إس بي سي قبل وبعد حقن أو إزالة القسطرة في المواعيد المُحددة من قبل الطبيب المعالج لك تمامًا.</p><p dir="RTL">&bull; أخبر الطبيب المعالج لك فورًا إذا أصبت بتنميل أو ضعف في الساقين أو مشاكل بالأمعاء أو المثانة بعد نهاية عملية التخدير، لأنه من الضروري الحصول على الرعاية العاجلة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاستخدام في المرضى من الأطفال والمراھقین</strong><strong>:</strong></p><p dir="RTL"><strong>لا يوصى بإعطاء </strong>دواء ريفاروكسابان إس بي سي 15 مجم و 20 مجم أقرا ص <strong>للمرضى الذين يقل وزن أجسامهم عن 30 كجم</strong>.</p><p dir="RTL">لا توجد معلومات كافية حول استخدام دواء ريفاروكسابان إس بي سي 15 مجم و 20 مجم أقراص في قسم دواعي الاستعمال في المرضى من البالغين بشأن فئة المرضى من الأطفال والمراهقين.</p><p dir="RTL"><strong>تناوُل دواء ريفاروكسابان إس بي سي مع الأدوية الأخرى</strong><strong>:</strong></p><p dir="RTL">أخبر الطبيب المعالج لك أو الصيدلي الخاص بك إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أية أدوية أخرى، بما في ذلك الأدوية التي حصلت عليها دون وصفة طبية.</p><p dir="RTL">- إذا كنت تتناول أية من الأدوية التالية:</p><p dir="RTL">&bull; بعض الأدوية التي تستخدم لعلاج العدوى الفطرية (مثل فلوكونازول وإيتراكونازول وفوريكونازول وبوساكونازول) ، إلا إذا كانت تستخدم وتوضع على الجلد فقط.</p><p dir="RTL">&bull; كیتوكونازول أقراص (دواء يسُتخدم في علاج مرض متلازمة كوشينج، عندما يزداد إنتاج الجسم لهرمون الكورتیزول بمعدل زائد عن المعدل الطبيعي).</p><p dir="RTL">&bull; بعض الأدوية التي تستخدم لعلاج حالا ت العدوى البكتيرية (مثل كلاريثروميسين&nbsp;وإريثروميسين).</p><p dir="RTL">&bull; بعض الأدوية المضادة للفيروسات التي تستخدم لعلاج فيروس نقص المناعة البشري /(HIV) متلازمة نقص المناعة المكتسبة (AIDS) مثل (ريتونافير).</p><p dir="RTL">&bull; الأدوية الأخرى التي تستخدم لتقليل تجلط الدمَّ (مثل إينوكسابارين&nbsp;وكلوبيدوجريل&nbsp;أو مضادات فيتامين كيه مثل وارفارين واكينوكيومارول).</p><p dir="RTL">&bull; الأدوية المضادة للالتهاب والأدوية المسكنة للألم (مثل: نابروكسين&nbsp;أو حمض الأسيتيل&nbsp;ساليسيلك).</p><p dir="RTL">&bull; دواء درونيدارون، هو دواء يستخدم لعلاج ضربات القلب غير الطبيعية.</p><p dir="RTL">&bull; بعض الأدوية التي تستخدم لعلاج الاكتئاب (مثبطات إعادة امتصاص السيروتونين&nbsp;الانتقائية&nbsp;&quot;SSRIs&quot; أو مثبطات استرداد السيروتونين والنورابينفرين&nbsp;(&quot;SNRIs&quot;)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أخبر الطبيب المعالج لك </strong>قبل تناول دواء ريفاروكسابان إس بي سي، <strong>إذا انطبقت عليك أي حالة من</strong><strong> </strong><strong>الحالات السابقة، لأن هذا قد يؤثر على زيادة فعالية دواء ريفاروكسابان إس بي سي</strong>. سيقرر الطبيب<strong> </strong>المعالج ما إذا كان يجب علاجك بهذا الدواء وما إذا كان يتوجب متابعة حالتك الصحية عن قرب.</p><p dir="RTL"><strong>يمكن أن يصف الطبيب المعالج لك علاج وقائي لمنع الإصابة بالقرحة، إذا كان يعتقد زيادة معدل خطر تعرضك لاضطرابات في المعدة أو الإصابة بقرح هضمية.</strong></p><p dir="RTL">&minus; إذا كنت تتناول أي من الأدوية التالية:</p><p dir="RTL">&bull; بعض الأدوية التي تستخدم لعلاج مرض الصرع (فينيتوين وكاربامازيبين&nbsp;وفينوباربيتال).</p><p dir="RTL">&bull; عشبة سانت جونز (هايبيريكم&nbsp;بيرفراتم) ، منتج عشبي يتم استخدامه لعلاج الاكتئاب.</p><p dir="RTL">&bull; ريفامبيسين&nbsp;(دواء يسُتخدم كمضاد حيوي).</p><p dir="RTL"><strong>أخبر الطبيب المعالج لك، إذا انطبق عليك أي من الأعراض السابقة، </strong>قبل تناول دواء ريفاروكسابان إس بي سي، لأن هذا قد يؤدي إلى انخفاض فعالية دواء ريفاروكسابان إس بي سي. سيقرر الطبيب المعالج لك، ما إذا كان يجب علاجك بدواء ريفاروكسابان إس بي سي، وما إذا كان يتوجب متابعة حالتك الصحية عن قرب.</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong><strong>:</strong></p><p dir="RTL">يحظر عليك تناولِ دواء ريفاروكسابان إس بي سي، <strong>إذا كنتِ حاملاً أو تمارسين الرضاعة الطبيعية.</strong></p><p dir="RTL">يرجى استخدام وسيلة فعالة لمنع الحمل، إذا كانت هناك احتمال أن تصبحين حاملاً، أثناء فترة العلاج بدواء ريفاروكسابان إس بي سي. أخبري الطبيب المعالج لكِ فورًا، إذا أصبحت حاملاً أثناء فترة تناول هذا الدواء، والذي سيحدد طريقة العلاج المناسبة لكِ.</p><p dir="RTL"><strong>قيادة السيارات واستخدام الآلات</strong></p><p dir="RTL">يمكن أن يسبب دواء ريفاروكسابان إس بي سي دوخة (أثر جانبي شائع) أو حالات إغماء (أثر جانبي غير شائع) (انظر القسم رقم: 4 &quot;آثار جانبية مُحتمَلة&quot;). يحضر قيادة السيارات أو استخدام الآلات أو الماكينات</p><p dir="RTL">إذا شعرت بأي من الأعراض السابقة.</p><p dir="RTL"><strong>يحتوي دواء ريفاروكسابان إس بي سي على اللاكتوز والصوديوم</strong><strong>:</strong></p><p dir="RTL">إذا أخبرك الطبيب المعالج لك بأنك لا تتحمل بعض أنواع السكريات، فيرُجى الاتصال به قبل تناول هذا الدواء. يحتوي هذا الدواء على أقل من 1 مللي مول من الصوديوم (23 مجم) في كل قرص، مما يعني أن الدواء شبه &quot;خال من الصوديوم&quot; بشكل أساسي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول هذا الدواء دائمًا كما أخبرك الطبيب المعالج لك تمامًا. يُرجى مراجعة الطبيب المعالج لك أو الصيدلي الخاص بكِ إذا لم تكن متأكدا من كيفية تناول هذا الدواء.</p><p dir="RTL">يمكن تناول دواء ريفاروكسابان إس بي سي 15 مجم و 20 مجم أقراص مع الطعام.</p><p dir="RTL">يفُضل بلع القرص كاملاً مع شرب كوب من الماء.</p><p dir="RTL">يرجى استشارة الطبيب المعالج لك، إذا كنت تواجه صعوبة في ابتلاع القرص بأكمله، حول الطرق الأخرى المتاحة لتناول دواء ريفاروكسابان إس بي سي، فيمكن أن يتم طحن القرص وخلطه مع الماء أو مع التفاح المهروس مباشرًة قبل تناوله. يجب أن يتم تناول بعض الطعام بعد تناول هذا الخليط مباشرةً.</p><p dir="RTL">قد يقوم الطبيب المعالج لك، إذا لزم الأمر، بإعطائك قر ص مسحوق من دواء ريفاروكسابان إس بي سي بواسطة أنبوب داخل المعدة.</p><p dir="RTL"><strong>ما هي الكمية التي يجب أن تتناولها</strong><strong>:</strong></p><p dir="RTL">&bull; <strong>فئة المرضى من البالغين</strong></p><p dir="RTL">- في حالة استخدام الدواء لمنع تكوُّن الجلطات الدموية في المخ (السكتة الدماغية) وفي الأوعية الدموية الأخرى بالجسم، <strong>الجرعة الموصى بها هي قرص واحد من دواء ريفاروكسابان إس بي</strong> <strong>سي 20 مجم مرة واحدة يومياً</strong>.</p><p dir="RTL">- إذا كنت تعاني من مشاكل بالكلى، فيمكن تقليل الجرعة إلى قرص واحد من دواء <strong>ريفاروكسابان إس بي سي </strong>15 مجم <strong>مرة واحدة يومياً.</strong></p><p dir="RTL">- إذا كنت بحاجة إلى إجراء علاجي لانسداد الأوعية الدموية بالقلب (يسمى التدخل التاجي عن طريق الجلد- PCI مع إدخال دعامة) ، فهناك براهين محدودة لتقليل الجرعة إلى قرص واحد من دواء ريفاروكسابان إس بي سي 15 مجم مرة واحدة يومياً (أو إلى قرص واحد من ريفاروكسابان إس بي سي 10 مجم مرة واحدة يومياً في حالة عدم أداء الكليتان لوظائفهما بشكل طبيعي) بالإضافة إلى منتج دوائي مضاد للصفيحات مثل كلوبيدوجريل...</p><p dir="RTL">- في حالة استخدام الدواء لعلاج جلطات الدم في أوردة الساق وجلطات الدم في الأوعية الدموية داخل الرئة ولمنع تكرار حدوث جلطات الدم مرة أخرى، فإن الجرعة الموصي بها هي قرص واحد من ريفاروكسابان إس بي سي 15 مجم مرتان يومياً في أول 3 أسابيع، والجرعة الموصي بها بعد انتهاء 3 أسابيع هي قرص واحد من ريفاروكسابان إس بي سي 20 مجم مرة واحدة يومياً، وبعد مرور 6 أشهر على الأقل من علاج جلطات الدم، فقد يقرر الطبيب المعالج لك الاستمرار في تناول إما قرص واحد 10 مجم مرة يومياً أو قرص واحد 20 مجم يومياً.</p><p dir="RTL">- إذا كنت تعاني من مشاكل في الكلى وتتناول قرص واحد من ريفاروكسابان إس بي سي 20 مجم مرة واحدة يومياً، فقد يقرر طبيبك الخاص تقليل جرعة العلاج بعد 3 أسابيع إلى قرص واحد من ريفاروكسابان إس بي سي 15 مجم مرة واحدة يومياً في حالة أن يكون مخاطر النزيف أكبر من مخاطر الإصابة بجلطة دموية أخرى.</p><p dir="RTL">&bull; <strong>فئة المرضى من الأطفال والمراهقين</strong></p><p dir="RTL">تعتمد جرعة ريفاروكسابان إس بي سي على وزن الجسم، وسيحسب الطبيب مقدار هذا الوزن.</p><p dir="RTL">&bull; الجرعة الموصى بها للمرضى من الأطفال والمراهقين&nbsp;الذين يتراوح مقدار أوزانهم بين 30 كجم وأقل من 50 كجم هي قرص واحد من ريفاروكسابان إس بي سي 15 مجم مرة واحدة يومياً.</p><p dir="RTL">&bull; الجرعة الموصى بها للمرضى من الأطفال والمراهقين ذوى وزن مقداره 50 كجم أو أكثر هي قرص واحد من ريفاروكسابان إس بي سي 20 مجم مرة واحدة يومياً.</p><p dir="RTL">تناول كل جرعة من ريفاروكسابان إس بي سي مع شراب (على سبيل المثال، ماء أو عصير) أثناء الطعام. تناول الأقراص يومياً في الوقت نفسه تقريباً. ضع في اعتبارك ضبط منبه لتذكيرك بمواعيد تناول الدواء.</p><p dir="RTL">يرجى مراقبة الطفل للتأكد من أنه قد تناول الجرعة كاملة من قبل الوالدين أو مقدمي الرعاية.</p><p dir="RTL">بما أن جرعات دواء ريفاروكسابان إس بي سي تعتمد على وزن الجسم، فإنه من الضروري أن يلتزم المريض بمواعيد زيارات الطبيب لأن الجرعة قد تحتاج إلى تعديل وفقاً لتغيرات وزن الجسم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحضر عليك تعديل جرعة ريفاروكسابان إس بي سي بمفردك دون استشارة الطبيب. سيقوم الطبيب بتعديل الجرعة إذا كان ذلك ضرورياً.</p><p dir="RTL">يحضر تقسيم القرص في محاولة لتناول جزء أصغر منه في الجرعة.</p><p dir="RTL">بالنسبة للمرضى من الأطفال والمراھقین غير القادرين على بلع الأقراص كاملة أو في حالة الحاجة إلى جرعة أقل، يمكنك طحن قر ص من دواء ريفاروكسابان إس بي سي وخلطه مع الماء أو مع التفاح المهروس مباشرًة قبل تناوله. تناول بعض الطعام بعد تلقى هذا الخليط. قد يقوم الطبيب المعالج لك، إذا لزم الأمر، بإعطائك قرص مطحون من دواء ريفاروكسابان إس بي سي بواسطة أنبوب داخل المعدة.</p><p dir="RTL"><strong>إذا بصقت الجرعة أو تقيأت</strong></p><p dir="RTL"><strong>- </strong>إذا مر أقل من 30 دقيقة بعد أن تم تناول دواء ريفاروكسابان إس بي سي، قم بتناول جرعة جديدة.</p><p dir="RTL"><strong>- </strong>إذا مر أكثر من 30 دقيقة بعد أن تم تناول دواء ريفاروكسابان إس بي سي، يحظر تناول جرعة جديدة. وفي هذه الحالة، تناول الجرعة التالية من دواء ريفاروكسابان إس بي سي في الميعاد الطبيعي لها.</p><p dir="RTL"><strong>- </strong>تواصل مع الطبيب المعالج إذا كنت تبصق أو تتقيأ الجرعة بعد تناول دواء ريفاروكسابان إس بي سي.</p><p dir="RTL"><strong>موعد تتناول دواء ريفاروكسابان إس بي سي</strong><strong>:</strong></p><p dir="RTL">استمر في تناول دواء ريفاروكسابان إس بي سي أقرا ص يوميًا ما لم يخبرك الطبيب المعالج لك بإيقاف العلاج.</p><p dir="RTL">ينبغي الحرص على تناول القرص (الأقراص) في نفس الوق ت من كل يوم فهذا يساعدك على تذكر موعد الجرعات.</p><p dir="RTL">سيقرر الطبيب المعالج لك المدة الزمنية اللازمة للاستمرار في تناول العلاج.</p><p dir="RTL">يجب أن تتناول ريفاروكسابان إس بي سي في الأوقات التي يحددها لك الطبيب لمنع تكوُّن الجلطات الدموية في المخ (السكتة الدماغية) وفي الأوعية الدموية الأخرى بالجسم: إذا كانت ضربات قلبك بحاجة إلى استعادة وضعها الطبيعي من خلال إجراء يسمى تقويم نظم القلب.</p><p dir="RTL"><strong>إذا تناولت كمية أكثر مما يجب من دواء ريفاروكسابان إس بي سي</strong><strong>:</strong></p><p dir="RTL"><strong>يرجى الاتصال فورًا بالطبيب المعالج لك، </strong>إذا كنت قد تناولت كمية كبيرة من دواء ريفاروكسابان إس بي سي أقراص. تناول كمية كبيرة من دواء ريفاروكسابان إس بي سي يزيد من خطر الإصابة بالنزيف.</p><p dir="RTL"><strong>إذا نسيت تناوُل دواء ريفاروكسابان إس بي سي</strong><strong>:</strong></p><p dir="RTL"><strong>المرضى من البالغين والأطفال والمراھقین</strong><strong>:</strong></p><p dir="RTL">إذا كنت تتناول قرص 20 مجم أو قرص 15 م جم مرة واحدة يومياً ونسيت تناول إحدى الجرعات، فتناولها بمجرد تذكرك لها. يحضر تناول أكثر من قرص واحد يومياً لتعويض جرعة قد نسيت تناولها.</p><p dir="RTL">تناول الجرعة التالية في اليوم التالي ثم استمر في تناول قرص واحد يومياً على النحو المعتاد.</p><p dir="RTL"><strong>المرضى من البالغين</strong></p><p dir="RTL">إذا كنت تتناول قرص 15 مجم مرتين يومياً ونسيت تناول إحدى الجرعات، فتناولها بمجرد تذكرك لها.</p><p dir="RTL">يحضر تناول أكثر من قرصين 15 مجم في يوم واحد. إذا نسيت تناول إحدى الجرعات، يمكنك تناول قرصين 15 مجم في الوقت نفسه لكي تحصل على إجمالي (30 مجم) من القرصين في يوم واحد. في اليوم التالي، ينبغي الاستمرار في تناول قرص واحد 15 مجم مرتين يومياً بالشكل المعتاد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن تناول دواء ريفاروكسابان إس بي سي</strong><strong>:</strong></p><p dir="RTL">لا تتوقف عن تناول دواء ريفاروكسابان إس بي سي بدون استشارة الطبيب المعالج لك أولًا، لأن دواء ريفاروكسابان إس بي سي يساهم في العلاج من بعض الحالات الخطرة والوقاية منها.</p><p dir="RTL">إذا كانت لديك أي أسئلة إضافية حول استخدام هذا الدواء، فاستشر الطبيب المعالج لك أو مقدم الرعاية الصحية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">قد يسبب دواء ريفاروكسابان إس بي سي، مثله مثل كافة الأدوية، آثار جانبية على الرغم من عدم حدوثها لجميع المرضى.</p><p dir="RTL">كما يمكن أن يسبب دواء ريفاروكسابان إس بي سي، مثله مثل كافة الأدوية المشابهة الأخرى (الأدوية المانعة لتجلط الدم)، نزيفاً قد يكون مُهددا للحياة. يؤدي النزيف الشديد إلى حدوث هبوط مفاجئ في ضغط الدمَّ (الإصابة بالصدمة). وقد لا يكون النزيف واضحًا في بعض الحالات.</p><p dir="RTL"><strong>آثار جانبية مُحتملة قد تدل على الإصابة بالنزيف</strong><strong>:</strong></p><p dir="RTL"><strong>أخبر الطبيب المعالج فورًا إذا تعرضت أنت أو طفلك لأي من الآثار الجانبية التالية</strong><strong>:</strong></p><p dir="RTL">- نزيف في الدماغ أو داخل الجمجمة (قد تشمل الأعراض على صداع، ضعف في جانب واحد من الجسم، قيء، نوبات تشنجية، انخفاض مستوى الوعي، وتيبس الرقبة وهي حالة طبية طارئة خطيرة. يجب أن تسعى للحصول على رعاية طبية عاجلة)</p><p dir="RTL">- وجود نزيف شديد أو مستمر لفترة طويلة.</p><p dir="RTL">- حالات ضعف غير اعتيادية، تعب، شحوب، دوخة، صداع، تورم غير مبرر، ضيق في التنفس، ألم بالصدر أو ذبحة صدرية، وقد تكون هذه علامات الإصابة بالنزيف.</p><p dir="RTL">قد يقرر الطبيب المعالج لك إبقائك تحت الملاحظة عن قرب أو تغيير طريقة العلاج.</p><p dir="RTL"><strong>آثار جانبية مُحتملة قد تدل على الإصابة بتفاعل جلدي شديد</strong><strong>:</strong></p><p dir="RTL">أخبر الطبيب المعالج لك فورًا، إذا تعرضت لتفاعلات جلدية على النحو التالي:</p><p dir="RTL">- طفح جلدي شديد منتشر بالجسم، بثور وحالات عدوي بالأنسجة المخاطية، على سبيل المثال في الفم أو العينين (متلازمة ستيفنز جونسون/تقشر الأنسجة المتموتة البشروية التسممي). يحدث هذا التأثير الجانبي بصورة نادرة جداً (يوثر على مريض واحد من بين كل 10.000 مريض).</p><p dir="RTL">- تفاعل دوائي يؤدي إلى الإصابة بطفح جلدي، حمى، التهاب الأعضاء الداخلية، اضطرابات الدم واضطراب منتشر في مختلف أجهزة الجسم (متلازمة رد الفعل الدوائي مع فرط الحمضات والأعراض الجهازية التي تعرف ايضًا باسم &quot;DRESS&rdquo; أو متلازمة فرط الحساسية للأدوية).</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;يحدث هذا التأثير الجانبي بصورة نادرة جدًا يؤثر على مريض واحد من بين كل 10.000 مريض.</p><p dir="RTL"><strong>آثار جانبية مُحتملة قد تدل على الإصابة بتفاعلات حساسية شديدة</strong><strong>:</strong></p><p dir="RTL">أخبر الطبيب المعالج لك فورًا إذا تعرضت لأي من الآثار الجانبية التالية:</p><p dir="RTL">- تورّم بالوجه، الشفًتَين، الفم، اللسان أو الحلق; صعوبة في البلع; شرى &quot;ارتكاريا&quot; وصعوبة في التنفس; هبوط مفاجئ في ضغط الدم. تحدث هذه الآثار الجانبية بصورة نادرة جداً (تفاعلات تأقية (حساسية) والتي تشمل صدمة الحساسية التي قد تؤُثر على ما يصل إلى مريض واحد من بين كل 10,000 مريض) وآثر جانبية غير شائعة (وذمة وعائية ووذمة حساسية التي قد تؤثر على ما يصل إلى مريض واحد من بين كل 100 مريض).</p><p dir="RTL"><strong>قائمة شاملة بالآثار الجانبية المحتملة التي قد وجُدت في المرضى من البالغين والأطفال والمراهقين</strong><strong>:</strong></p><p dir="RTL"><strong>آثار جانبية شائعة (قد تؤثر على ما يصل إلى مريض واحد من بين كل 10 مرضى)</strong><strong>:</strong></p><p dir="RTL">- انخفاض في خلايا الدم الحمراء مما يؤدي إلى شحوب في لون البشرة و ضعف أو ضيق بالتنفس.</p><p dir="RTL">- نزيف بالمعدة أو الأمعاء، نزيف من الجهاز البولي التناسلي (يشمل نزول الدم مع البول ونزيف غزير غير معتاد أثناء فترة الحيض) ، نزيف من الأنف، نزيف من اللثة.</p><p dir="RTL">- نزيف داخل العين (بما في ذلك نزيف من المنطقة البيضاء من العينين).</p><p dir="RTL">- نزيف داخلي في الأنسجة أو في التجويف الداخلي بالجسم (تجمع دموي، كدمات).</p><p dir="RTL">- سعال مصحوب بدم.</p><p dir="RTL">- نزيف من الجلد أو من الأنسجة الموجودة تحت الجلد.</p><p dir="RTL">- نزيف بعد الخضوع لأية عملية جراحية.</p><p dir="RTL">- نزول دم أو سوائل من فتحة أو جرح (قطع) العملية الجراحية.</p><p dir="RTL">- تورم بالأطراف.</p><p dir="RTL">- ألم بالأطراف.</p><p dir="RTL">- خلل في وظائف الكُلى (يمكن ملاحظتها من نتائج الفحوصات التي يطُلبها الطبيب المعالج لك)</p><p dir="RTL">- حُمى.</p><p dir="RTL">- ألم بالمعدة، عسر هضم، شعور بإعياء أو مرض، إمساك، إسهال.</p><p dir="RTL">- انخفاض ضغط الدمَّ (قد تشتمل الأعراض على شعور بدوخة أو إغماء عند الوقوف).</p><p dir="RTL">- انخفاض عام في قوة الجسم البدنية وطاقته (ضعف وتعب) صداع، دوخة.</p><p dir="RTL">- طفح جلدي، حكة جلدية.</p><p dir="RTL">- قد تظهر فحوصا ت الدم ارتفاع في بعض إنزيمات الكبد.</p><p dir="RTL"><strong>آثار جانبية غير شائعة (قد تؤُثر على ما يصل إلى مريض واحد من بين كل 100 مريض)</strong></p><p dir="RTL">- نزيف داخل الدماغ أو داخل الجمجمة.</p><p dir="RTL">- نزيف في أحد مفاصل الجس م مما يسبب ألم وتورم.</p><p dir="RTL">- انخفاض بالصفيحات الدموية (انخفاض في عدد الصفائح الدموية، وهي الخلايا التي تساعد على تجلط الدم).</p><p dir="RTL">- تفاعلات حساسية (بما في ذلك تفاعلات حساسية بالجلد).</p><p dir="RTL">- انخفاض وظائف الكب د (يظهر ذلك في الفحوصات التي يطلبها الطبيب المعالج لك).</p><p dir="RTL">- قد تظهر فحوصات الدم ارتفاع في مستوى البيليروبين، بعض انزيمات البنكرياس أو الكبد أو ارتفاع في عدد الصفائح الدموية.</p><p dir="RTL">- إغماء.</p><p dir="RTL">- شعور بإعياء (توعُّك).</p><p dir="RTL">- زيادة ضربات القلَبْ.</p><p dir="RTL">- جُفافُ الفمَ.</p><p dir="RTL">- شرى (ارتكاريا).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية نادرة (قد تؤُثر على ما يصل إلى مريض واحد من بين كل 1,000 مريض)</strong><strong>:</strong></p><p dir="RTL">- نزيف بالعضلات.</p><p dir="RTL">- ركود صفراوي (انخفاضٌ في تدفقّ العصارة الصفراوية) التهاب الكبد بما في ذلك إصابة الخلايا الكبدية (التهاب الكبد بما في ذلك الإصابات الكبدية).</p><p dir="RTL">- اصفرار الجلد والعينين (يرقان).</p><p dir="RTL">- تورم موضعي.</p><p dir="RTL">- تجمع دموي (ورم دموي) في الفخذ نتيجة حدوث مضاعفات عقب التدخل الجراحي بالقلب حيث يتم إدخال قسطرة للقلب من داخل شريان الساق (تمدد الأوعية الدموية الكاذب).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية غير معروف معدّل تكرارها (لا يمكن تقدير معدل التكرار من واقع البيانات المتاحة)</strong><strong>:</strong></p><p dir="RTL">- فشل كلوي عق ب الإصابة بنزيف شديد.</p><p dir="RTL">- ارتفاع الضغط داخل عضلات الساقين أو الذراعين عقب الإصابة بالنزيف، مما يسبب ألم، تورم ، تغير في الإحساس، تنميل أو شلل (متلازمة الحيزّ أو المقصورة بعد التعرض للنزيف &quot;هي زيادة في الضغط في داخل حيزّ في الجسم حول عضلاتٍ أو أعصاب مُعينَّة وهي تحدث عندما تتورّم العضلات أو الأعصاب المصابة بشكلٍ كبير بحيث تنقطع عنها التروية&quot;).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية في المرضى من الأطفال والمراهقين</strong><strong>:</strong></p><p dir="RTL">كانت الآثار الجانبية التي لوحظت في المرضى من الأطفال والمراهقين مماثلة، بصفة عامة، للآثار الجانبية المتعلقة بالمرضى من البالغين الذين تم علاجهم باستخدام دواء ريفاروكسابان إس بي سي حيث تراوحت حدتها من خفيفة إلى معتدلة في الخطورة.</p><p dir="RTL">تم ملاحظة آثار جانبية بشكل أكثر تكرار في المرضى من الأطفال والمراهقين:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية شائعة جدًا (قد تؤُثر على أكثر من مريض واحد من بين كل 10 مرضى)</strong><strong>:</strong></p><p dir="RTL">- صداع.</p><p dir="RTL">- حمّى.</p><p dir="RTL">- نزيف بالأنف.</p><p dir="RTL">- قيء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية شائعة: (قد تؤُثر على ما يصل إلى مريض واحد من بين كل 10 مرضى)</strong><strong>:</strong></p><p dir="RTL">- تسارع ضربات القلب.</p><p dir="RTL">- قد تظهر فحوصات الدم زيادة في البيبيروبين (العصارة الصفراوية).</p><p dir="RTL">- قلة الصفيحات (انخفاض عدد الصفائح الدموية وهي خلايا تساعد الدم على تجلط الدم).</p><p dir="RTL">- نزيف كثيف غير طبيعي أثناء فترة الحيض.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية غير شائعة (قد تؤثر على ما يصل إلى مريض واحد من بين كل 100 مريض)</strong></p><p dir="RTL">- قد تظهر فحوصا ت الدم زيادة في الفئات الفرعية من البيبيروبين (البيبيروبين المباشر واللون الصفراوي).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong><strong>:</strong></p><p dir="RTL">إن كان لديك أعرا ض جانبية أو لاحظت أعراض جانبية غير مذكورة في هذه النشرة، فضلاً ابلغ &lt; الطبيب&gt; &lt;أو&gt;&lt;مقدم الرعاية الصحية&gt;&lt;أو&gt; &lt;الصيدلي&gt;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحُفظَ هذا الدواء في درجة حرارة تقل عن 30 &deg; درجة مئوية.</p><p dir="RTL">يحُفظ هذا الدوَّاء بعيداً عن رؤية ومتناول الأطفال.</p><p dir="RTL">يحضر تناول هذا الدواء بعد انتهاء تاريخ الصلاحية المدون على العبوة الكرتونية وعلى كل شريط أو على الزجاجة بعد كلمة &quot;EXP&quot;.</p><p dir="RTL">يشُير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">لا يحتاج هذا الدوَّاء إلى أي شروط خاصة للحفظ.</p><p dir="RTL">يجب عدم التخلص من الأدوية عن طريق إلقائها عبر مياه الصرف الصحي أو مع النفايات المنزلية. استشر الصيدلي الخاص بك عن كيفية التخَّلص من الأدوية التي لم تعَدُ تستخدمها. سوف تسُاعد هذه الإجراءات على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>المادة الفعالة </strong>هي ريفاروكسابان.</p><p dir="RTL">يحتوي كل قرص على 15 مجم أو 20 مجم من ريفاروكسابان<strong>.</strong></p><p dir="RTL">المكونات الأخرى: سليولوز دقيق التبلور وكروس كارميلوز الصوديوم ولاكتوز احادي الھيدرات وھيبروميلوز (5 CPS) وكبريتات لوريل الصوديوم وستيرات المغنسيوم وأوبادري ذات لون وردي 4F540025 وأوبادري ذات لون بني 04F565014 وأوبادري ذات لون أحمر 04F550002.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>دواء ريفاروكسابان إس بي سي 15 مجم أقراص</strong></p><p dir="RTL">أقراص مُغلفَّة ذات لون أحمر، دائرية الشكل، ثنائية التحدبُّ (بقطر: 6 ملم تقريبا) محفور على أحد جانبيها &quot;15&rdquo; والجانب الآخر أملس.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ريفاروكسابان إس بي سي 20 مجم أقراص</strong></p><p dir="RTL">أقراص مُغلفَّة ذات لون أحمر غامق، دائرية الشكل، ثنائية التحدبُّ (بقطر: 6 ملم تقريبا) محفور على أحد جانبيها &quot;20&quot; والجانب الآخر أملس.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك حق التصريح بالتسويق</strong><strong>:</strong></p><p dir="RTL">شركة سدير فارما (SPC)</p><p dir="RTL">طريق الملك فهد، مبنى 8006 -</p><p dir="RTL">الرياض 4432، المملكة العربية السعودية</p><p dir="RTL">هاتف: 920001432 -11-966+</p><p dir="RTL">فاكس: 4668195 -11-966+</p><p dir="RTL">البريد الإلكتروني: info@sudairpharma.com</p><p dir="RTL">عنوان المراسلة: صندوق بريد رقم: 12363، الرياض، المملكة العربية السعودية</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الشركة المصنعة</strong><strong>:</strong></p><p dir="RTL">شركة دكتور ريدي لابروتيرز ليمتد</p><p dir="RTL">الوحدة الثانية الخاصة بالتصنيع/ قطعة أرض رقم 42,45,46،</p><p dir="RTL">قرية باتشوبالي</p><p dir="RTL">قطوبولابور ماندال،</p><p dir="RTL">مقاطعة رانجا ريدي</p><p dir="RTL">تيلانجانا، الهند 500090،</p><p dir="RTL">الهند</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت آخر مراجعة لهذه النشرة بتاريخ 02/2021
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Rivaroxaban SPC 15 mg tablet and 20 mg tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Rivaroxaban SPC 15 mg tablets 
Each film coated tablet contains 15 mg of Rivaroxaban 

Rivaroxaban SPC 20 mg tablets
Each film coated tablet contains 20 mg of Rivaroxaban

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet  
Rivaroxaban SPC 15 mg tablets 
Red colored, round biconvex film coated tablet (Diameter: Approximately 6 mm), engraved with ‘15’ on one side and plain on the other side. 

Rivaroxaban SPC 20 mg tablets
Dark red colored, round biconvex film coated tablet (Diameter: Approximately 6 mm), engraved with ‘20’ on one side and plain on the other side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Adult Population</u></p><p>Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age &ge; 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.</p><p>Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically PE patients.)</p><p><u>Paediatric population</u></p><p>Treatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing 30 kg or more after at least 5 days of initial parenteral anticoagulation treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p><em>Prevention of stroke and systemic embolism</em></p><p>The recommended dose is 20 mg once daily, which is also the recommended maximum dose.</p><p>Therapy with Rivaroxaban SPC should be continued long term provided the benefit of prevention of stroke and systemic embolism outweighs the risk of bleeding (see section 4.4).</p><p>If a dose is missed the patient should take Rivaroxaban SPC immediately and continue on the following day with the once daily intake as recommended. The dose should not be doubled within the same day to make up for a missed dose.</p><p>&nbsp;</p><p><!--[if gte vml 1]><o:wrapblock><v:shape
  id="Graphic_x0020_3" o:spid="_x0000_s2053" style='position:absolute;
  margin-left:70.55pt;margin-top:17.55pt;width:454.2pt;height:.5pt;z-index:-15728640;
  visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:0;
  mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
  mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
  mso-position-vertical:absolute;mso-position-vertical-relative:text;
  v-text-anchor:top' coordsize="5768340,6350" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" path="m5768340,l,,,6350r5768340,l5768340,xe" fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p><em>Treatment of DVT, treatment of PE and prevention of recurrent DVT and PE</em></p><p>The recommended dose for the initial treatment of acute DVT or PE is 15 mg twice daily for the first three weeks followed by 20 mg once daily for the continued treatment and prevention of recurrent DVT and PE.</p><p>Short duration of therapy (at least 3 months) should be considered in patients with DVT or PE provoked by major transient risk factors (i.e. recent major surgery or trauma). Longer duration of therapy should be considered in patients with provoked DVT or PE not related to major transient risk factors, unprovoked DVT or PE, or a history of recurrent DVT or PE.</p><p>When extended prevention of recurrent DVT and PE is indicated (following completion of at least 6 months therapy for DVT or PE), the recommended dose is 10 mg once daily. In patients in whom the risk of recurrent DVT or PE is considered high, such as those with complicated comorbidities, or who have developed recurrent DVT or PE on extended prevention with Rivaroxaban SPC 10 mg once daily, a dose of Rivaroxaban SPC 20 mg once daily should be considered.</p><p>The duration of therapy and dose selection should be individualized after careful assessment of the treatment benefit against the risk for bleeding (see section 4.4).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td><p><strong>Time period</strong></p></td><td><p><strong>Dosing schedule</strong></p></td><td><p><strong>Total daily dose</strong></p></td></tr><tr><td rowspan="2"><p>Treatment and</p><p>prevention of recurrent DVT and PE</p></td><td><p>Day 1 &ndash; 21</p></td><td><p>15 mg twice daily</p></td><td><p>30 mg</p></td></tr><tr><td><p>Day 22 onwards</p></td><td><p>20 mg once daily</p></td><td><p>20 mg</p></td></tr><tr><td><p>Prevention of recurrent DVT and PE</p></td><td><p>Following completion of at least 6 months therapy for DVT or PE</p></td><td><p>10 mg once daily or 20 mg once daily</p></td><td><p>10 mg</p><p>or 20 mg</p></td></tr></tbody></table><p>To support the dose switch from 15 mg to 20 mg after Day 21 a first 4 weeks treatment initiation pack of Rivaroxaban SPC for treatment of DVT/PE is available.</p><p>If a dose is missed during the 15 mg twice daily treatment phase (day 1 - 21), the patient should take Rivaroxaban SPC immediately to ensure intake of 30 mg Rivaroxaban SPC per day. In this case two 15 mg tablets may be taken at once. The patient should continue with the regular 15 mg twice daily intake as recommended on the following day.</p><p>If a dose is missed during the once daily treatment phase, the patient should take Rivaroxaban SPC immediately, and continue on the following day with the once daily intake as recommended. The dose should not be doubled within the same day to make up for a missed dose.</p><p>&nbsp;</p><p><em>Treatment of VTE and prevention of VTE recurrence in children and adolescents</em></p><p><em>&nbsp;</em></p><p>Rivaroxaban SPC treatment in children and adolescents aged less than 18 years should be initiated following at least 5 days of initial parenteral anticoagulation treatment (see section 5.1).</p><p>The dose for children and adolescent is calculated based on body weight.</p><p>-&nbsp; Body weight of 50 kg or more:</p><p>a once daily dose of 20 mg rivaroxaban is recommended. This is the maximum daily dose.</p><p>-&nbsp; Body weight from 30 to 50 kg:</p><p>a once daily dose of 15 mg rivaroxaban is recommended. This is the maximum daily dose.</p><p>The weight of a child should be monitored and the dose reviewed regularly. This is to ensure a therapeutic dose is maintained. Dose adjustments should be made based on changes in body weight only.</p><p>Treatment should be continued for at least 3 months in children and adolescents. Treatment can be extended up to 12 months when clinically necessary. There is no data available in children to support a dose reduction after 6 months treatment. The benefit-risk of continued therapy after 3 months should be assessed on an individual basis taking into account the risk for recurrent thrombosis versus the potential bleeding risk.</p><p>&nbsp;</p><p>If a dose is missed, the missed dose should be taken as soon as possible after it is noticed, but only on the same day. If this is not possible, the patient should skip the dose and continue with the next dose as prescribed. The patient should not take two doses to make up for a missed dose.</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Converting from Vitamin K Antagonists (VKA) to Rivaroxaban SPC</em></p><p>For patients treated for prevention of stroke and systemic embolism, VKA treatment should be stopped and Rivaroxaban SPC therapy should be initiated when the International Normalised Ratio (INR) is &le; 3.0.</p><p>For patients treated for DVT, PE and prevention of recurrence, VKA treatment should be stopped and Rivaroxaban SPC therapy should be initiated once the INR is &le; 2.5.</p><p>When converting patients from VKAs to Rivaroxaban SPC, INR values will be falsely elevated after the intake of Rivaroxaban SPC. The INR is not valid to measure the anticoagulant activity of Rivaroxaban SPC, and therefore should not be used (see section 4.5).</p><p>&nbsp;</p><p><em>Converting from Rivaroxaban SPC to Vitamin K antagonists (VKA)</em></p><p>There is a potential for inadequate anticoagulation during the transition from Rivaroxaban SPC to VKA. Continuous adequate anticoagulation should be ensured during any transition to an alternate anticoagulant. It should be noted that Rivaroxaban SPC can contribute to an elevated INR.</p><p>In patients converting from Rivaroxaban SPC to VKA, VKA should be given concurrently until the INR is &ge; 2.0. For the first two days of the conversion period, standard initial dosing of VKA should be used followed by VKA dosing, as guided by INR testing. While patients are on both Rivaroxaban SPC and VKA the INR should not be tested earlier than 24 hours after the previous dose but prior to the next dose of Rivaroxaban SPC. Once Rivaroxaban SPC is discontinued INR testing may be done reliably at least 24 hours after the last dose (see sections 4.5 and 5.2).</p><p>&nbsp;</p><p><em>Paediatric patients:</em></p><p>Children who convert from Rivaroxaban SPC to VKA need to continue Rivaroxaban SPC for 48 hours after the first dose of VKA. After 2 days of co-administration an INR should be obtained prior to the next scheduled dose of Rivaroxaban SPC. Co-administration of Rivaroxaban SPC and VKA is advised to continue until the INR is &ge; 2.0. Once Rivaroxaban SPC is discontinued INR testing may be done reliably 24 hours after the last dose (see above and section 4.5).</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Converting from parenteral anticoagulants to Rivaroxaban SPC</em></p><p>For patients currently receiving a parenteral anticoagulant, discontinue the parenteral anticoagulant and start Rivaroxaban SPC 0 to 2 hours before the time that the next scheduled administration of the parenteral medicinal product (e.g. low molecular weight heparins) would be due or at the time of discontinuation of a continuously administered parenteral medicinal product (e.g. intravenous unfractionated heparin).</p><p>&nbsp;</p><p><em>Converting from Rivaroxaban SPC to parenteral anticoagulants</em></p><p>Discontinue Rivaroxaban SPC and give the first dose of parenteral anticoagulant at the time the next Rivaroxaban SPC dose would be taken.</p><p>&nbsp;</p><p><u>Special populations</u></p><p><em>Renal impairment</em></p><p>&nbsp;</p><p>Limited clinical data for patients with severe renal impairment (creatinine clearance 15 - 29 ml/min) indicate that Rivaroxaban plasma concentrations are significantly increased. Therefore, Rivaroxaban SPC is to be used with caution in these patients. Use is not recommended in patients with creatinine clearance &lt; 15 ml/min (see sections 4.4 and 5.2).</p><p>In patients with moderate (creatinine clearance 30 - 49 ml/min) or severe (creatinine clearance 15 - 29 ml/min) renal impairment the following dose recommendations apply:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, the recommended dose is 15 mg once daily (see section 5.2).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For the treatment of DVT, treatment of PE and prevention of recurrent DVT and PE: patients should be treated with 15 mg twice daily for the first 3 weeks. Thereafter, when the recommended dose is 20 mg once daily, a reduction of the dose from 20 mg once daily to 15 mg once daily should be considered if the patient&#39;s assessed risk for bleeding outweighs the risk for recurrent DVT and PE. The recommendation for the use of 15 mg is based on PK modelling and has not been studied in this clinical setting (see sections 4.4, 5.1 and 5.2).</p><p>When the recommended dose is 10 mg once daily, no dose adjustment from the recommended dose is necessary.</p><p>No dose adjustment is necessary in patients with mild renal impairment (creatinine clearance 50 - 80 ml/min) (see section 5.2).</p><p>&nbsp;</p><p><em>Paediatric population:</em></p><p>-&nbsp; Children and adolescents with mild renal impairment (glomerular filtration rate 50 - 80 mL/min/1.73 m2): no dose adjustment is required, based on data in adults and limited data in paediatric patients (see section 5.2).</p><p>-&nbsp; Children and adolescents with moderate or severe renal impairment (glomerular filtration rate &lt; 50 mL/min/1.73 m2): Rivaroxaban SPC is not recommended as no clinical data is available (see section 4.4).</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>Rivaroxaban SPC is contraindicated in patients with hepatic disease associated with coagulopathy and clinically relevant bleeding risk including cirrhotic patients with Child Pugh B and C (see sections 4.3 and 5.2).</p><p>&nbsp;</p><p>No clinical data is available in children with hepatic impairment.</p><p>&nbsp;</p><p><em>Elderly population</em></p><p>No dose adjustment (see section 5.2)</p><p>&nbsp;</p><p><em>Body weight</em></p><p>No dose adjustment (see section 5.2)</p><p>&nbsp;</p><p>For paediatric patients the dose is determined based on body weight.</p><p><em>Gender</em></p><p>No dose adjustment (see section 5.2)</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The safety and efficacy of Rivaroxaban SPC in children aged 0 to 18 years have not been established in the indication prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation. No data are available. Therefore, it is not recommended for use in children below 18 years of age in indications other than the treatment of VTE and prevention of VTE recurrence.</p><p>&nbsp;</p><p><em>Patients undergoing cardioversion</em></p><p>Rivaroxaban SPC can be initiated or continued in patients who may require cardioversion.</p><p>For transesophageal echocardiogram (TEE) guided cardioversion in patients not previously treated with anticoagulants, Rivaroxaban SPC treatment should be started at least 4 hours before cardioversion to ensure adequate anticoagulation (see sections 5.1 and 5.2). For all patients, confirmation should be sought prior to cardioversion that the patient has taken Rivaroxaban SPC as prescribed. Decisions on initiation and duration of treatment should take established guideline recommendations for anticoagulant treatment in patients undergoing cardioversion into account.</p><p>&nbsp;</p><p><em>Patients with non-valvular atrial fibrillation who undergo PCI (percutaneous coronary intervention) with stent placement</em></p><p>There is limited experience of a reduced dose of 15 mg Rivaroxaban SPC once daily (or 10 mg Rivaroxaban SPC once daily for patients with moderate renal impairment [creatinine clearance 30 - 49 ml/min]) in addition to a P2Y12 inhibitor for a maximum of 12 months in patients with non-valvular atrial fibrillation who require oral anticoagulation and undergo PCI with stent placement (see sections 4.4 and 5.1).</p><p>&nbsp;</p><p><u>Method of administration</u></p><p><em>Adults</em></p><p>Rivaroxaban SPC is for oral use.</p><p>The tablets are to be taken with food (see section 5.2).</p><p>&nbsp;</p><p><em><u>Crushing of tablets</u></em></p><p>For patients who are unable to swallow whole tablets, Rivaroxaban SPC tablet may be crushed and mixed with water or apple puree immediately prior to use and administered orally. After the administration of crushed Rivaroxaban SPC 15 mg or 20 mg film-coated tablets, the dose should be immediately followed by food.</p><p>The crushed Rivaroxaban SPC tablet may also be given through gastric tubes (see sections 5.2 and 6.6).</p><p>&nbsp;</p><p><em>Children and adolescents weighing 30 kg or more</em></p><p><em>&nbsp;</em></p><p>Rivaroxaban SPC is for oral use.</p><p>The patient should be advised to swallow the tablet with liquid. It should also be taken with food (see section 5.2). The tablets should be taken approximately 24 hours apart.</p><p>In case the patient immediately spits up the dose or vomits within 30 minutes after receiving the dose, a new dose should be given. However, if the patient vomits more than 30 minutes after the dose, the dose should not be re-administered and the next dose should be taken as scheduled.</p><p>&nbsp;</p><p>The tablet must not be split in an attempt to provide a fraction of a tablet dose.</p><p><em><u>Crushing of tablets</u></em></p><p>For patients who are unable to swallow whole tablets, Rivaroxaban SPC tablet may be crushed and mixed with water or apple puree immediately prior to use and administered orally.</p><p>The crushed tablet may be given through a nasogastric or gastric feeding tube (see sections 5.2 and 6.6).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Active clinically significant bleeding.
Lesion or condition, if considered to be a significant risk for major bleeding. This may include current or recent gastrointestinal ulceration, presence of malignant neoplasms at high risk of bleeding, recent brain or spinal injury, recent brain, spinal or ophthalmic surgery, recent intracranial haemorrhage, known or suspected oesophageal varices, arteriovenous malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities.
Concomitant treatment with any other anticoagulants, e.g. unfractionated heparin (UFH), low molecular weight heparins (enoxaparin, dalteparin, etc.), heparin derivatives (fondaparinux, etc.), oral anticoagulants (warfarin, dabigatran etexilate, apixaban, etc.) except under specific circumstances of switching anticoagulant therapy (see section 4.2) or when UFH is given at doses necessary to maintain an open central venous or arterial catheter (see section 4.5).
Hepatic disease associated with coagulopathy and clinically relevant bleeding risk including cirrhotic patients with Child Pugh B and C (see section 5.2).
Pregnancy and breast-feeding (see section 4.6).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clinical surveillance in line with anticoagulation practice is recommended throughout the treatment period.</p><p>&nbsp;</p><p><u>Haemorrhagic risk</u></p><p>As with other anticoagulants, patients taking Rivaroxaban SPC are to be carefully observed for signs of bleeding. It is recommended to be used with caution in conditions with increased risk of haemorrhage. Rivaroxaban SPC administration should be discontinued if severe haemorrhage occurs (see section 4.9).</p><p>In the clinical studies mucosal bleedings (i.e. epistaxis, gingival, gastrointestinal, genito urinary including abnormal vaginal or increased menstrual bleeding) and anaemia were seen more frequently during long term Rivaroxaban treatment compared with VKA treatment. Thus, in addition to adequate clinical surveillance, laboratory testing of haemoglobin/haematocrit could be of value to detect occult bleeding and quantify the clinical relevance of overt bleeding, as judged to be appropriate.</p><p>Several sub-groups of patients, as detailed below, are at increased risk of bleeding. These patients are to be carefully monitored for signs and symptoms of bleeding complications and anaemia after initiation of treatment.</p><p>Any unexplained fall in haemoglobin or blood pressure should lead to a search for a bleeding site.</p><p>Although treatment with Rivaroxaban does not require routine monitoring of exposure, Rivaroxaban levels measured with a calibrated quantitative anti-factor Xa assay may be useful in exceptional<u>&nbsp;situations where knowledge of Rivaroxaban exposure may help to inform clinical decisions, e.g.</u>&nbsp;overdose and emergency surgery (see sections 5.1 and 5.2).</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>There is limited data in children with cerebral vein and sinus thrombosis who have a CNS infection (see section 5.1). The risk of bleeding should be carefully evaluated before and during therapy with rivaroxaban.</p><p>&nbsp;</p><p><u>Renal impairment</u></p><p>In patients with severe renal impairment (creatinine clearance &lt; 30 ml/min) Rivaroxaban SPC plasma levels may be significantly increased (1.6 fold on average) which may lead to an increased bleeding risk. Rivaroxaban SPC is to be used with caution in patients with creatinine clearance 15 - 29 ml/min. Use is not recommended in patients with creatinine clearance &lt; 15 ml/min (see sections 4.2 and 5.2).</p><p>Rivaroxaban SPC should be used with caution in patients with renal impairment concomitantly receiving other medicinal products which increase Rivaroxaban plasma concentrations (see section 4.5).</p><p>Rivaroxaban SPC is not recommended in children and adolescents with moderate or severe renal impairment (glomerular filtration rate &lt; 50 mL/min/1.73 m2), as no clinical data is available.</p><p>&nbsp;</p><p><u>Interaction with other medicinal products</u></p><p>The use of Rivaroxaban SPC is not recommended in patients receiving concomitant systemic treatment with azole-antimycotics (such as ketoconazole, itraconazole, voriconazole and posaconazole) or HIV protease inhibitors (e.g. ritonavir). These active substances are strong inhibitors of both CYP3A4 and P-gp and therefore may increase Rivaroxaban plasma concentrations to a clinically relevant degree (2.6 fold on average) which may lead to an increased bleeding risk. No clinical data is available in children receiving concomitant systemic treatment with strong inhibitors of both CYP3A4 and P-gp (see section 4.5).</p><p>Care is to be taken if patients are treated concomitantly with medicinal products affecting haemostasis such as non-steroidal anti-inflammatory medicinal products (NSAIDs), acetylsalicylic acid and platelet aggregation inhibitors or selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs). For patients at risk of ulcerative gastrointestinal disease an appropriate prophylactic treatment may be considered (see section 4.5).</p><p>&nbsp;</p><p><u>Other haemorrhagic risk factors</u></p><p>As with other antithrombotics, Rivaroxaban is not recommended in patients with an increased bleeding risk such as:</p><p>&bull;&nbsp; congenital or acquired bleeding disorders</p><p>&bull;&nbsp; uncontrolled severe arterial hypertension</p><p>&bull;&nbsp;&nbsp;&nbsp; other gastrointestinal disease without active ulceration that can potentially lead to bleeding complications (e.g. inflammatory bowel disease, oesophagitis, gastritis and gastroesophageal reflux disease)</p><p>&bull;&nbsp; vascular retinopathy</p><p>&bull;&nbsp; bronchiectasis or history of pulmonary bleeding <u>Patients with prosthetic valves</u></p><p>Rivaroxaban should not be used for thromboprophylaxis in patients having recently undergone transcatheter aortic valve replacement (TAVR). Safety and efficacy of Rivaroxaban SPC have not been studied in patients with prosthetic heart valves; therefore, there are no data to support that Rivaroxaban SPC provides adequate anticoagulation in this patient population. Treatment with Rivaroxaban SPC is not recommended for these patients.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Patients with anti-phospholipid syndrome</u></p><p>Direct acting Oral Anticoagulants (DOACs) including Rivaroxaban are not recommended for patients with a history of thrombosis who are diagnosed with antiphospholipid syndrome. In particular for patients that are triple positive (for lupus anticoagulant, anticardiolipin antibodies, and anti-beta 2- glycoprotein I antibodies), treatment with DOACs could be associated with increased rates of recurrent thrombotic events compared with vitamin K antagonist therapy.</p><p><u>Patients with non-valvular atrial fibrillation who undergo PCI with stent placement</u></p><p>Clinical data are available from an interventional study with the primary objective to assess safety in patients with non-valvular atrial fibrillation who undergo PCI with stent placement. Data on efficacy in this population are limited (see sections 4.2 and 5.1). No data are available for such patients with a history of stroke/TIA.</p><p><u>Haemodynamically unstable PE patients or patients who require thrombolysis or pulmonary</u> <u>embolectomy</u></p><p>Rivaroxaban SPC is not recommended as an alternative to unfractionated heparin in patients with pulmonary embolism who are haemodynamically unstable or may receive thrombolysis or pulmonary embolectomy since the safety and efficacy of Rivaroxaban SPC have not been established in these clinical situations.</p><p>&nbsp;</p><p><u>Spinal/epidural anaesthesia or puncture</u></p><p>When neuraxial anaesthesia (spinal/epidural anaesthesia) or spinal/epidural puncture is employed, patients treated with antithrombotic agents for prevention of thromboembolic complications are at risk of developing an epidural or spinal haematoma which can result in long-term or permanent paralysis. The risk of these events may be increased by the post-operative use of indwelling epidural catheters or the concomitant use of medicinal products affecting haemostasis. The risk may also be increased by traumatic or repeated epidural or spinal puncture. Patients are to be frequently monitored for signs and symptoms of neurological impairment (e.g. numbness or weakness of the legs, bowel or bladder dysfunction). If neurological compromise is noted, urgent diagnosis and treatment is necessary. Prior to neuraxial intervention the physician should consider the potential benefit versus the risk in anticoagulated patients or in patients to be anticoagulated for thromboprophylaxis. There is no clinical experience with the use of 15mg, 20 mg Rivaroxaban in these situations.</p><p>To reduce the potential risk of bleeding associated with the concurrent use of Rivaroxaban and neuraxial (epidural/spinal) anaesthesia or spinal puncture, consider the pharmacokinetic profile of Rivaroxaban. Placement or removal of an epidural catheter or lumbar puncture is best performed when the anticoagulant effect of Rivaroxaban is estimated to be low. However, the exact timing to reach a sufficiently low anticoagulant effect in each patient is not known.</p><p>For the removal of an epidural catheter and based on the general PK characteristics at least 2x half-life,</p><p>i.e. at least 18 hours in young patients and 26 hours in elderly patients should elapse after the last administration of Rivaroxaban (see section 5.2). Following removal of the catheter, at least 6 hours should elapse before the next Rivaroxaban dose is administered.</p><p>If traumatic puncture occurs the administration of Rivaroxaban is to be delayed for 24 hours.</p><p>No data is available on the timing of the placement or removal of neuraxial catheter in children while on Rivaroxaban SPC. In such cases, discontinue rivaroxaban and consider a short acting parenteral anticoagulant.</p><p>&nbsp;</p><p><u>Dosing recommendations before and after invasive procedures and surgical intervention</u></p><p>If an invasive procedure or surgical intervention is required, Rivaroxaban SPC 15mg and 20 mg should be stopped at least 24 hours before the intervention, if possible and based on the clinical judgement of the physician.</p><p>If the procedure cannot be delayed the increased risk of bleeding should be assessed against the urgency of the intervention.</p><p>Rivaroxaban SPC should be restarted as soon as possible after the invasive procedure or surgical intervention provided the clinical situation allows and adequate haemostasis has been established as determined by the treating physician (see section 5.2).</p><p>&nbsp;</p><p><u>Elderly population</u></p><p>Increasing age may increase haemorrhagic risk (see section 5.2).</p><p>&nbsp;</p><p><u>Dermatological reactions</u></p><p>Serious skin reactions, including Stevens-Johnson syndrome/toxic epidermal necrolysis and DRESS syndrome, have been reported during post-marketing surveillance in association with the use of Rivaroxaban (see section 4.8). Patients appear to be at highest risk for these reactions early in the course of therapy: the onset of the reaction occurring in the majority of cases within the first weeks of treatment. Rivaroxaban should be discontinued at the first appearance of a severe skin rash (e.g. spreading, intense and/or blistering), or any other sign of hypersensitivity in conjunction with mucosal lesions.</p><p>&nbsp;</p><p><u>Information about excipients</u></p><p>Rivaroxaban SPC contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.</p><p>This medicinal product contains less than 1 mmol sodium (23 mg) per dosage unit, that is to say essentially &ldquo;sodium-free&rdquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>CYP3A4 and P-gp inhibitors</u></p><p>Co-administration of Rivaroxaban with ketoconazole (400 mg once a day) or ritonavir (600 mg twice a day) led to a 2.6 fold / 2.5 fold increase in mean Rivaroxaban AUC and a 1.7 fold / 1.6 fold increase in mean Rivaroxaban Cmax, with significant increases in pharmacodynamic effects which may lead to an increased bleeding risk. Therefore, the use of Rivaroxaban is not recommended in patients receiving concomitant systemic treatment with azole-antimycotics such as ketoconazole, itraconazole, voriconazole and posaconazole or HIV protease inhibitors. These active substances are strong inhibitors of both CYP3A4 and P-gp.</p><p>Active substances strongly inhibiting only one of the Rivaroxaban elimination pathways, either CYP3A4 or P-gp, are expected to increase Rivaroxaban plasma concentrations to a lesser extent. Clarithromycin (500 mg twice a day), for instance, considered as a strong CYP3A4 inhibitor and moderate P-gp inhibitor, led to a 1.5 fold increase in mean Rivaroxaban AUC and a 1.4 fold increase in Cmax. The interaction with clarithromycin is likely not clinically relevant in most patients but can be potentially significant in high-risk patients.</p><p>Erythromycin (500 mg three times a day), which inhibits CYP3A4 and P-gp moderately, led to a 1.3 fold increase in mean Rivaroxaban AUC and Cmax. The interaction with erythromycin is likely not clinically relevant in most patients but can be potentially significant in high-risk patients.</p><p>In subjects with mild renal impairment erythromycin (500 mg three times a day) led to a 1.8 fold <u>increase in mean Rivaroxaban AUC and 1.6 fold increase in C</u><u>max when compared to subjects with</u>&nbsp;normal renal function. In subjects with moderate renal impairment, erythromycin led to a 2.0 fold increase in mean Rivaroxaban AUC and 1.6 fold increase in Cmax when compared to subjects with normal renal function. The effect of erythromycin is additive to that of renal impairment.</p><p>Fluconazole (400 mg once daily), considered as a moderate CYP3A4 inhibitor, led to a 1.4 fold increase in mean Rivaroxaban AUC and a 1.3 fold increase in mean Cmax. The interaction with fluconazole is likely not clinically relevant in most patients but can be potentially significant in high-risk patients.</p><p>Given the limited clinical data available with dronedarone, co-administration with Rivaroxaban should be avoided.</p><p>&nbsp;</p><p><u>Anticoagulants</u></p><p>After combined administration of enoxaparin (40 mg single dose) with Rivaroxaban (10 mg single dose) an additive effect on anti-factor Xa activity was observed without any additional effects on clotting tests (PT, aPTT). Enoxaparin did not affect the pharmacokinetics of Rivaroxaban.</p><p>Due to the increased bleeding risk care is to be taken if patients are treated concomitantly with any other anticoagulants.</p><p>&nbsp;</p><p><u>NSAIDs/platelet aggregation inhibitors</u></p><p>No clinically relevant prolongation of bleeding time was observed after concomitant administration of Rivaroxaban (15 mg) and 500 mg naproxen. Nevertheless, there may be individuals with a more pronounced pharmacodynamic response.</p><p>No clinically significant pharmacokinetic or pharmacodynamic interactions were observed when Rivaroxaban was co-administered with 500 mg acetylsalicylic acid.</p><p>Clopidogrel (300 mg loading dose followed by 75 mg maintenance dose) did not show a pharmacokinetic interaction with Rivaroxaban (15 mg) but a relevant increase in bleeding time was observed in a subset of patients which was not correlated to platelet aggregation, P-selectin or GPIIb/IIIa receptor levels.</p><p>Care is to be taken if patients are treated concomitantly with NSAIDs (including acetylsalicylic acid) and platelet aggregation inhibitors because these medicinal products typically increase the bleeding risk.</p><p>&nbsp;</p><p><u>SSRIs/SNRIs</u></p><p>As with other anticoagulants the possibility may exist that patients are at increased risk of bleeding in case of concomitant use with SSRIs or SNRIs due to their reported effect on platelets. When concomitantly used in the Rivaroxaban clinical programme, numerically higher rates of major or non- major clinically relevant bleeding were observed in all treatment groups.</p><p>&nbsp;</p><p><u>Warfarin</u></p><p>Converting patients from the vitamin K antagonist warfarin (INR 2.0 to 3.0) to Rivaroxaban (20 mg) or from Rivaroxaban (20 mg) to warfarin (INR 2.0 to 3.0) increased prothrombin time/INR (Neoplastin) more than additively (individual INR values up to 12 may be observed), whereas effects on aPTT, inhibition of factor Xa activity and endogenous thrombin potential were additive.</p><p>If it is desired to test the pharmacodynamic effects of Rivaroxaban during the conversion period, anti- factor Xa activity, PiCT, and Heptest can be used as these tests were not affected by warfarin. On the fourth day after the last dose of warfarin, all tests (including PT, aPTT, inhibition of factor Xa activity and ETP) reflected only the effect of Rivaroxaban.</p><p>If it is desired to test the pharmacodynamic effects of warfarin during the conversion period, INR measurement can be used at the Ctrough of Rivaroxaban (24 hours after the previous intake of Rivaroxaban) as this test is minimally affected by Rivaroxaban at this time point.</p><p>No pharmacokinetic interaction was observed between warfarin and Rivaroxaban.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>CYP3A4 inducers</u></p><p>Co-administration of Rivaroxaban with the strong CYP3A4 inducer rifampicin led to an approximate 50% decrease in mean Rivaroxaban AUC, with parallel decreases in its pharmacodynamic effects. The concomitant use of Rivaroxaban with other strong CYP3A4 inducers (e.g. phenytoin, carbamazepine, phenobarbital or St. John&#39;s Wort <em>(Hypericum perforatum)</em>) may also lead to reduced Rivaroxaban plasma concentrations. Therefore, concomitant administration of strong CYP3A4 inducers should be avoided unless the patient is closely observed for signs and symptoms of thrombosis.</p><p><u>Other concomitant therapies</u></p><p>No clinically significant pharmacokinetic or pharmacodynamic interactions were observed when Rivaroxaban was co-administered with midazolam (substrate of CYP3A4), digoxin (substrate of P-gp), atorvastatin (substrate of CYP3A4 and P-gp) or omeprazole (proton pump inhibitor). Rivaroxaban neither inhibits nor induces any major CYP isoforms like CYP3A4.</p><p>No clinically relevant interaction with food was observed</p><p>&nbsp;</p><p><u>Laboratory parameters</u></p><p>Clotting parameters (e.g. PT, aPTT, HepTest) are affected as expected by the mode of action of Rivaroxaban.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>Safety and efficacy of Rivaroxaban have not been established in pregnant women. Studies in animals have shown reproductive toxicity. Due to the potential reproductive toxicity, the intrinsic risk of bleeding and the evidence that Rivaroxaban passes the placenta, Rivaroxaban is contraindicated during pregnancy.</p><p>Women of child-bearing potential should avoid becoming pregnant during treatment with Rivaroxaban.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>Safety and efficacy of Rivaroxaban have not been established in breast-feeding women. Data from animals indicate that Rivaroxaban is secreted into milk. Therefore Rivaroxaban is contraindicated during breast-feeding. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from therapy.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>No specific studies with Rivaroxaban in humans have been conducted to evaluate effects on fertility. In a study on male and female fertility in rats no effects were seen.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Rivaroxaban has minor influence on the ability to drive and use machines. Adverse reactions like syncope (frequency: uncommon) and dizziness (frequency: common) have been reported. Patients experiencing these adverse reactions should not drive or use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>The safety of Rivaroxaban has been evaluated in thirteen phase III studies including 53,103 patients exposed to Rivaroxaban and in two phase II and one phase III paediatric studies including 412 patients. See phase III studies as listed in (Table 1).</p><p>Table 1: Number of patients studied, total daily dose and maximum treatment duration in phase III studies</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Indication</strong></p></td><td><p><strong>Number of patients*</strong></p></td><td><p><strong>Total daily dose</strong></p></td><td><p><strong>Maximum</strong></p><p><strong>treatment duration</strong></p></td></tr><tr><td><p>Prevention of venous thromboembolism (VTE) in adult</p><p>patients undergoing elective hip or knee replacement surgery</p></td><td><p><strong>&nbsp;</strong></p><p>6,097</p></td><td><p><strong>&nbsp;</strong></p><p>10 mg</p></td><td><p><strong>&nbsp;</strong></p><p>39 days</p></td></tr><tr><td><p>Prevention of VTE in medically ill patients</p></td><td><p>3,997</p></td><td><p>10 mg</p></td><td><p>39 days</p></td></tr><tr><td><p><strong>&nbsp;</strong></p><p>Treatment of DVT, PE and prevention of recurrence</p></td><td><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>6,790</p></td><td><p>Day 1 - 21: 30 mg Day 22 and onwards: 20 mg</p><p>After at least 6</p><p>months: 10 mg or 20 mg</p></td><td><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>21 months</p></td></tr><tr><td><p>Treatment of VTE and prevention of VTE recurrence in term neonates and children aged less than 18 years following initiation of standard anticoagulation</p><p>treatment</p></td><td><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>329</p></td><td><p>Body weight- adjusted dose to achieve a similar exposure as that observed in adults treated for DVT with 20 mg rivaroxaban</p><p>once daily</p></td><td><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>12 months</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="width:442px"><p>Prevention of stroke and systemic embolism in patients with non- valvular atrial fibrillation</p></td><td style="width:98px"><p>7,750</p></td><td><p>20 mg</p></td><td><p>41 months</p></td></tr><tr><td style="width:442px"><p><strong>&nbsp;</strong></p><p>Prevention of atherothrombotic events in patients after an acute coronary syndrome (ACS)</p></td><td style="width:98px"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>10,225</p></td><td><p>5 mg or 10 mg respectively, co- administered with either ASA or ASA</p><p>plus clopidogrel or ticlopidine</p></td><td><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>31 months</p></td></tr><tr><td style="width:442px"><p>Prevention of atherothrombotic events in patients with CAD/PAD</p></td><td style="width:98px"><p>18,244</p></td><td><p>5 mg co-administered with ASA or 10 mg alone</p></td><td><p>47 months</p></td></tr><tr><td colspan="4"><p>* Patients exposed to at least one dose of Rivaroxaban</p></td></tr></tbody></table><p>The most commonly reported adverse reactions in patients receiving Rivaroxaban were bleedings. The most commonly reported bleedings were epistaxis (4.5 %) and gastrointestinal tract haemorrhage (3.8%).</p><p>Table 2: Bleeding* and anaemia events rates in patients exposed to Rivaroxaban across the completed adult and paediatric phase III studies</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Indication</strong></p></td><td><p><strong>Any bleeding</strong></p></td><td><p><strong>Anaemia</strong></p></td></tr><tr><td><p>Prevention of VTE in adult patients</p><p>undergoing elective hip or knee replacement surgery</p></td><td><p>6.8% of patients</p></td><td><p>5.9% of patients</p></td></tr><tr><td><p>Prevention of VTE in medically ill patients</p></td><td><p>12.6% of patients</p></td><td><p>2.1% of patients</p></td></tr><tr><td><p>Treatment of DVT, PE and prevention of recurrence</p></td><td><p>23% of patients</p></td><td><p>1.6% of patients</p></td></tr><tr><td><p>Prevention of stroke and systemic embolism</p><p>in patients with non-valvular atrial fibrillation</p></td><td><p>28 per 100 patient years</p></td><td><p>2.5 per 100 patient years</p></td></tr><tr><td><p>Prevention of atherothrombotic events in patients after an ACS</p></td><td><p>22 per 100 patient years</p></td><td><p>1.4 per 100 patient years</p></td></tr><tr><td><p>Prevention of atherothrombotic events in patients with CAD/PAD</p></td><td><p>6.7 per 100 patient years</p></td><td><p>0.15 per 100 patient years**</p></td></tr><tr><td colspan="3"><p>* For all Rivaroxaban studies all bleeding events are collected, reported and adjudicated.</p><p>** In the COMPASS study, there is a low anaemia incidence as a selective approach to adverse event collection was applied</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><u>Tabulated list of adverse reactions</u></p><p>The frequencies of adverse reactions reported with Rivaroxaban are summarised in Table 3 below by system organ class (in MedDRA) and by frequency.</p><p>Frequencies are defined as:</p><p>very common (&ge; 1/10)</p><p>common (&ge; 1/100 to &lt; 1/10)</p><p>uncommon (&ge; 1/1,000 to &lt; 1/100)</p><p>rare (&ge; 1/10,000 to &lt; 1/1,000)</p><p>very rare ( &lt; 1/10,000)</p><p>not known (cannot be estimated from the available data)</p><p>&nbsp;</p><p>Table 3: All adverse reactions reported in patients in phase III clinical trials or post-marketing use* and in two phase II and one phase III studies in paediatric patients.</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Common</strong></p></td><td><p><strong>Uncommon</strong></p></td><td><p><strong>Rare</strong></p></td><td><p><strong>Very rare</strong></p></td><td><p><strong>Not known</strong></p></td></tr><tr><td colspan="5"><p><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td><p>Anaemia (incl. respective</p><p>laboratory parameters)</p></td><td><p>Thrombocytosis (incl. platelet count</p><p>increased)<sup>A</sup>, Thrombocytopenia</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="5"><p><strong>Immune system disorders</strong></p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Allergic reaction, dermatitis allergic, Angioedema and allergic oedema</p></td><td><p>&nbsp;</p></td><td><p>Anaphylactic reactions including</p><p>anaphylactic shock</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="5"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td><p>Dizziness, headache</p></td><td><p>Cerebral and intracranial</p><p>haemorrhage, syncope</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="5"><p><strong>Eye disorders</strong></p></td></tr><tr><td><p>Eye haemorrhage</p><p>(incl. conjunctival haemorrhage)</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="5"><p><strong>Cardiac disorders</strong></p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Tachycardia</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="5"><p><strong>Vascular disorders</strong></p></td></tr><tr><td><p>Hypotension, haematoma</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="5"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td><p>Epistaxis, haemoptysis</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="5"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td><p>Gingival bleeding, gastrointestinal tract haemorrhage (incl. rectal haemorrhage), gastrointestinal and abdominal pains, dyspepsia, nausea, constipation<sup>A</sup>, diarrhoea, vomiting<sup>A</sup></p></td><td><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>Dry mouth</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="5"><p><strong>Hepatobiliary disorders</strong></p></td></tr><tr><td><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>Increase in transaminases</p></td><td><p>Hepatic impairment, Increased bilirubin, increased blood alkaline phosphatase<sup>A</sup>, increased GGT<sup>A</sup></p></td><td><p>Jaundice, Bilirubin conjugated increased (with or without concomitant increase of ALT),</p><p>Cholestasis, Hepatitis (incl.hepatocellular injury)</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="5"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="width:341px"><p>Pruritus (incl. uncommon cases of generalised pruritus), rash, ecchymosis, cutaneous and subcutaneous</p><p>haemorrhage</p></td><td style="width:310px"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>Urticaria</p></td><td style="width:228px"><p>&nbsp;</p></td><td style="width:84px"><p>Stevens- Johnson syndrome/ Toxic Epidermal Necrolysis , DRESS</p><p>syndrome</p></td><td style="width:67px"><p>&nbsp;</p></td></tr><tr><td colspan="5"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="width:341px"><p><strong>&nbsp;</strong></p><p>Pain in extremity<sup>A</sup></p></td><td style="width:310px"><p><strong>&nbsp;</strong></p><p>Haemarthrosis</p></td><td style="width:228px"><p>Muscle haemorrhage</p></td><td style="width:84px"><p>&nbsp;</p></td><td style="width:67px"><p>Compartment syndrome secondary to a bleeding</p></td></tr><tr><td colspan="5"><p><strong>Renal and urinary disorders</strong></p></td></tr><tr><td style="width:341px"><p>Urogenital tract haemorrhage (incl. haematuria and menorrhagia<sup>B</sup>), renal impairment (incl. blood creatinine increased, blood urea increased)</p></td><td style="width:310px"><p>&nbsp;</p></td><td style="width:228px"><p>&nbsp;</p></td><td style="width:84px"><p>&nbsp;</p></td><td style="width:67px"><p>Renal failure/acute renal failure secondary to a bleeding sufficient to cause hypoperfusion</p></td></tr><tr><td colspan="5"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="width:341px"><p>Fever<sup>A</sup>, peripheral oedema, decreased general strength and energy (incl.</p><p>fatigue and asthenia)</p></td><td style="width:310px"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>Feeling unwell (incl. malaise)</p></td><td style="width:228px"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>Localised oedema<sup>A</sup></p></td><td style="width:84px"><p>&nbsp;</p></td><td style="width:67px"><p>&nbsp;</p></td></tr><tr><td colspan="5"><p><strong>Investigations</strong></p></td></tr><tr><td style="width:341px"><p>&nbsp;</p></td><td style="width:310px"><p>Increased LDH<sup>A</sup>,</p><p>increased lipase<sup>A</sup>, increased amylase<sup>A</sup></p></td><td style="width:228px"><p>&nbsp;</p></td><td style="width:84px"><p>&nbsp;</p></td><td style="width:67px"><p>&nbsp;</p></td></tr><tr><td colspan="5"><p><strong>Injury, poisoning and procedural complications</strong></p></td></tr><tr><td style="width:341px"><p>Postprocedural haemorrhage (incl. postoperative anaemia, and wound haemorrhage), contusion, wound secretion<sup>A</sup></p></td><td style="width:310px"><p>&nbsp;</p></td><td style="width:228px"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>Vascular pseudoaneurysm<sup>C</sup></p></td><td style="width:84px"><p>&nbsp;</p></td><td style="width:67px"><p>&nbsp;</p></td></tr><tr><td colspan="5"><p>A: observed in prevention of VTE in adult patients undergoing elective hip or knee replacement surgery</p><p>B: observed in treatment of DVT, PE and prevention of recurrence as very common in women &lt; 55 years</p><p>C: observed as uncommon in prevention of atherothrombotic events in patients after an ACS (following percutaneous coronary intervention)</p></td></tr></tbody></table><p>* A pre-specified selective approach to adverse event collection was applied. As incidence of adverse reactions did not increase and no new adverse reaction was identified, COMPASS study data were not included for frequency calculation in this table.</p><p><strong>&nbsp;</strong><br /><!--[if gte vml 1]><v:shapetype id="_x0000_t75"
 coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
 filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1025" type="#_x0000_t75" style='width:450.85pt;height:38.55pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p><u>Description of selected adverse reactions</u></p><p>Due to the pharmacological mode of action, the use of Rivaroxaban may be associated with an increased risk of occult or overt bleeding from any tissue or organ which may result in post haemorrhagic anaemia. The signs, symptoms, and severity (including fatal outcome) will vary according to the location and degree or extent of the bleeding and/or anaemia. In the clinical studies mucosal bleedings (i.e. epistaxis, gingival, gastrointestinal, genito urinary including abnormal vaginal or increased menstrual bleeding) and anaemia were seen more frequently during long term Rivaroxaban treatment compared with VKA treatment. Thus, in addition to adequate clinical surveillance, laboratory testing of haemoglobin/haematocrit could be of value to detect occult bleeding and quantify the clinical relevance of overt bleeding, as judged to be appropriate. The risk of bleedings may be increased in certain patient groups, e.g. those patients with uncontrolled severe arterial hypertension and/or on concomitant treatment affecting haemostasis. Menstrual bleeding may be intensified and/or prolonged. Haemorrhagic complications may present as weakness, paleness, dizziness, headache or unexplained swelling, dyspnoea and unexplained shock. In some cases as a consequence of anaemia, symptoms of cardiac ischaemia like chest pain or angina pectoris have been observed.</p><p>Known complications secondary to severe bleeding such as compartment syndrome and renal failure due to hypoperfusion have been reported for Rivaroxaban. Therefore, the possibility of haemorrhage is to be considered in evaluating the condition in any anticoagulated patient.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>The safety assessment in children and adolescents is based on the safety data from two phase II and one phase III open-label active controlled studies in paediatric patients aged birth to less than 18 years. The safety findings were generally similar between rivaroxaban and comparator in the various paediatric age groups. Overall, the safety profile in the 412 children and adolescents treated with rivaroxaban was similar to that observed in the adult population and consistent across age subgroups, although assessment is limited by the small number of patients.</p><p>In paediatric patients, headache (very common, 16.7%), fever (very common, 11.7%), epistaxis (very common, 11.2%), vomiting (very common, 10.7%), tachycardia (common, 1.5%), increase in bilirubin (common, 1.5%) and bilirubin conjugated increased (uncommon, 0.7%) were reported more frequently as compared to adults. Consistent with adult population, menorrhagia was observed in 6.6% (common) of female adolescents after menarche. Thrombocytopenia as observed in the post-marketing experience in adult population was common (4.6%) in paediatric clinical studies. The adverse drug reactions in paediatric patients were primarily mild to moderate in severity.</p><p>&nbsp;</p><p><u>To reports any side effect(s):</u></p><p><strong>Saudi Arabia:</strong></p><p><!--[if gte vml 1]><o:wrapblock><v:shape
  id="Textbox_x0020_21" o:spid="_x0000_s1027" type="#_x0000_t202" style='position:absolute;
  margin-left:67.9pt;margin-top:13pt;width:471.75pt;height:81.75pt;z-index:-15727104;
  visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:0;
  mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
  mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
  mso-position-vertical:absolute;mso-position-vertical-relative:text;
  v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" strokeweight="1.44pt">
  <v:path arrowok="t"/>
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText style='margin-top:.95pt;margin-right:0in;margin-bottom:
     0in;margin-left:23.4pt;margin-bottom:.0001pt;text-indent:-18.05pt;
     mso-list:l2 level1 lfo5;tab-stops:23.4pt'><![if !supportLists]><span
     style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
     Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
     </span></span></span><![endif]><span dir=LTR></span>The<span
     style='letter-spacing:-.3pt'> </span>National<span style='letter-spacing:
     -.2pt'> </span>Pharmacovigilance<span style='letter-spacing:-.25pt'> </span>Centre<span
     style='letter-spacing:-.35pt'> </span><span style='letter-spacing:-.1pt'>(NPC):</span><o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:12.45pt'><o:p>&nbsp;</o:p></p>
     <p class=MsoBodyText style='margin-left:23.35pt;text-indent:-.25in;
     mso-list:l1 level1 lfo4;tab-stops:23.35pt'><![if !supportLists]><span
     style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
     </span></span><![endif]><span dir=LTR></span>SFDA<span style='letter-spacing:
     -.2pt'> </span>Call<span style='letter-spacing:-.1pt'> </span>Center:<span
     style='letter-spacing:-.1pt'> 19999</span><o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:.65pt;margin-right:0in;margin-bottom:
     0in;margin-left:23.35pt;margin-bottom:.0001pt;text-indent:-.25in;
     mso-list:l1 level1 lfo4;tab-stops:23.35pt'><![if !supportLists]><span
     style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
     </span></span><![endif]><span dir=LTR></span>E-mail:<span
     style='letter-spacing:-.1pt'> </span><a href="mailto:npc.drug@sfda.gov.sa"><span
     style='color:#0461C1;letter-spacing:-.1pt'>npc.drug@sfda.gov.sa</span></a><o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:.7pt;margin-right:0in;margin-bottom:
     0in;margin-left:23.35pt;margin-bottom:.0001pt;text-indent:-.25in;
     mso-list:l1 level1 lfo4;tab-stops:23.35pt'><![if !supportLists]><span
     style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
     </span></span><![endif]><span dir=LTR></span>Website:<span
     style='letter-spacing:-.1pt'> <u style='text-underline:#0461C1'><span
     style='color:#0461C1'>https://ade.sfda.gov.sa/</span></u></span><o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC):</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: <u>https://ade.sfda.gov.sa/</u></p><p>&nbsp;</p><p><strong>Other GCC States:</strong></p><p><!--[if gte vml 1]><o:wrapblock><v:shape id="Textbox_x0020_22"
  o:spid="_x0000_s1026" type="#_x0000_t202" style='position:absolute;
  margin-left:67.9pt;margin-top:12.9pt;width:471.75pt;height:16.7pt;z-index:-15726592;
  visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:0;
  mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
  mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
  mso-position-vertical:absolute;mso-position-vertical-relative:text;
  v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" strokeweight="1.44pt">
  <v:path arrowok="t"/>
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText style='margin-top:1.0pt;margin-right:0in;margin-bottom:
     0in;margin-left:5.35pt;margin-bottom:.0001pt;tab-stops:23.35pt'><span
     style='letter-spacing:-.5pt'>-</span><span style='mso-tab-count:1'>     </span>Please<span
     style='letter-spacing:-.15pt'> </span>contact<span style='letter-spacing:
     -.25pt'> </span>the<span style='letter-spacing:-.2pt'> </span>relevant<span
     style='letter-spacing:-.25pt'> </span>competent<span style='letter-spacing:
     -.2pt'> </span><span style='letter-spacing:-.1pt'>authority.</span><o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]-->-&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In adult, rare cases of overdose up to 600 mg have been reported without bleeding complications or other adverse reactions. There is limited data available in children. Due to limited absorption a ceiling effect with no further increase in average plasma exposure is expected at supratherapeutic doses of 50 mg Rivaroxaban or above.</p><p>A specific reversal agent (andexanet alfa) antagonising the pharmacodynamic effect of rivaroxaban is available (refer to the Summary of Product Characteristics of andexanet alfa).</p><p>The use of activated charcoal to reduce absorption in case of Rivaroxaban overdose may be considered.</p><p>&nbsp;</p><p><u>Management of bleeding</u></p><p>Should a bleeding complication arise in a patient receiving Rivaroxaban, the next Rivaroxaban administration should be delayed or treatment should be discontinued as appropriate. Rivaroxaban has a half-life of approximately 5 to 13 hours. The half-life in children estimated using population pharmacokinetic (popPK) modelling approaches is shorter. Management should be individualised according to the severity and location of the haemorrhage. Appropriate symptomatic treatment could be used as needed, such as mechanical compression (e.g. for severe epistaxis), surgical haemostasis with bleeding control procedures, fluid replacement and haemodynamic support, blood products (packed red cells or fresh frozen plasma, depending on associated anaemia or coagulopathy) or platelets.</p><p>If bleeding cannot be controlled by the above measures, either the administration of a specific factor Xa inhibitor reversal agent (andexanet alfa), which antagonises the pharmacodynamic effect of rivaroxaban, or a specific procoagulant reversal agent should be considered, such as prothrombin complex concentrate (PCC), activated prothrombin complex concentrate (APCC) or recombinant factor VIIa (r-FVIIa). However, there is currently very limited clinical experience with the use of these medicinal products in adults and in children receiving Rivaroxaban. The recommendation is also based on limited non-clinical data. Re-dosing of recombinant factor VIIa shall be considered and titrated depending on improvement of bleeding.</p><p>Depending on local availability, a consultation with a coagulation expert should be considered in case of major bleedings.</p><p>Protamine sulphate and vitamin K are not expected to affect the anticoagulant activity of Rivaroxaban. There is limited experience with tranexamic acid and no experience with aminocaproic acid and aprotinin in adult receiving Rivaroxaban. There is no experience on the use of these agents in children receiving rivaroxaban. There is neither scientific rationale for benefit nor experience with the use of the systemic haemostatic desmopressin in individuals receiving Rivaroxaban. Due to the high plasma protein binding Rivaroxaban is not expected to be dialysable.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antithrombotic agents, direct factor Xa inhibitors.</p><p><u>Mechanism of action</u></p><p>Rivaroxaban is a highly selective direct factor Xa inhibitor with oral bioavailability. Inhibition of factor Xa interrupts the intrinsic and extrinsic pathway of the blood coagulation cascade, inhibiting both thrombin formation and development of thrombi. Rivaroxaban does not inhibit thrombin (activated factor II) and no effects on platelets have been demonstrated.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>Dose-dependent inhibition of factor Xa activity was observed in humans. Prothrombin time (PT) is influenced by Rivaroxaban in a dose dependent way with a close correlation to plasma concentrations (r value equals 0.98) if Neoplastin is used for the assay. Other reagents would provide different results. The readout for PT is to be done in seconds, because the INR is only calibrated and validated for coumarins and cannot be used for any other anticoagulant.</p><p>In patients receiving Rivaroxaban for treatment of DVT and PE and prevention of recurrence, the 5/95 percentiles for PT (Neoplastin) 2 - 4 hours after tablet intake (i.e. at the time of maximum effect) for 15 mg Rivaroxaban twice daily ranged from 17 to 32 s and for 20 mg Rivaroxaban once daily from 15 to 30 s. At trough (8 - 16 h after tablet intake) the 5/95 percentiles for 15 mg twice daily ranged from 14 to 24 s and for 20 mg once daily (18 - 30 h after tablet intake) from 13 to 20 s.</p><p>In patients with non-valvular atrial fibrillation receiving Rivaroxaban for the prevention of stroke and systemic embolism, the 5/95 percentiles for PT (Neoplastin) 1 - 4 hours after tablet intake (i.e. at the time of maximum effect) in patients treated with 20 mg once daily ranged from 14 to 40 s and in patients with moderate renal impairment treated with 15 mg once daily from 10 to 50 s. At trough (16 - 36 h after tablet intake) the 5/95 percentiles in patients treated with 20 mg once daily ranged from 12 to 26 s and in patients with moderate renal impairment treated with 15 mg once daily from 12 to 26 s.</p><p>In a clinical pharmacology study on the reversal of Rivaroxaban pharmacodynamics in healthy adult subjects (n=22), the effects of single doses (50 IU/kg) of two different types of PCCs, a 3-factor PCC (Factors II, IX and X) and a 4-factor PCC (Factors II, VII, IX and X) were assessed. The 3-factor PCC reduced mean Neoplastin PT values by approximately 1.0 second within 30 minutes, compared to reductions of approximately 3.5 seconds observed with the 4-factor PCC. In contrast, the 3-factor PCC had a greater and more rapid overall effect on reversing changes in endogenous thrombin generation than the 4-factor PCC (see section 4.9).</p><p>The activated partial thromboplastin time (aPTT) and HepTest are also prolonged dose-dependently; however, they are not recommended to assess the pharmacodynamic effect of Rivaroxaban. There is no need for monitoring of coagulation parameters during treatment with Rivaroxaban in clinical routine. However, if clinically indicated Rivaroxaban levels can be measured by calibrated quantitative anti- factor Xa tests (see section 5.2).</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>PT (neoplastin reagent), aPTT, and anti-Xa assay (with a calibrated quantitative test) display a close correlation to plasma concentrations in children. The correlation between anti-Xa to plasma concentrations is linear with a slope close to 1. Individual discrepancies with higher or lower anti-Xa values as compared to the corresponding plasma concentrations may occur. There is no need for routine monitoring of coagulation parameters during clinical treatment with rivaroxaban. However, if clinically indicated, rivaroxaban concentrations can be measured by calibrated quantitative anti-Factor Xa tests in mcg/L (see table 13 in section 5.2 for ranges of observed rivaroxaban plasma concentrations in children). The lower limit of quantifications must be considered when the anti-Xa test is used to quantify plasma concentrations of rivaroxaban in children. No threshold for efficacy or safety events has been established.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p><em>Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation</em></p><p>The Rivaroxaban clinical programme was designed to demonstrate the efficacy of Rivaroxaban for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation.</p><p>In the pivotal double-blind ROCKET AF study, 14,264 patients were assigned either to Rivaroxaban 20 mg once daily (15 mg once daily in patients with creatinine clearance 30 - 49 ml/min) or to warfarin titrated to a target INR of 2.5 (therapeutic range 2.0 to 3.0). The median time on treatment was 19 months and overall treatment duration was up to 41 months.</p><p>34.9% of patients were treated with acetylsalicylic acid and 11.4% were treated with class III antiarrhythmic including amiodarone.</p><p>Rivaroxaban was non-inferior to warfarin for the primary composite endpoint of stroke and non-CNS systemic embolism. In the per-protocol population on treatment, stroke or systemic embolism occurred in 188 patients on Rivaroxaban (1.71% per year) and 241 on warfarin (2.16% per year) (HR 0.79; 95% CI, 0.66 - 0.96; P&lt;0.001 for non-inferiority). Among all randomised patients analysed according to ITT, primary events occurred in 269 on Rivaroxaban (2.12% per year) and 306 on warfarin (2.42% per year) (HR 0.88; 95% CI, 0.74 - 1.03; P&lt;0.001 for non-inferiority; P=0.117 for superiority). Results for secondary endpoints as tested in hierarchical order in the ITT analysis are displayed in Table 4.</p><p>Among patients in the warfarin group, INR values were within the therapeutic range (2.0 to 3.0) a mean of 55% of the time (median, 58%; interquartile range, 43 to 71). The effect of Rivaroxaban did not differ across the level of centre TTR (Time in Target INR Range of 2.0 - 3.0) in the equally sized quartiles (P=0.74 for interaction). Within the highest quartile according to centre, the Hazard Ratio (HR) with Rivaroxaban versus warfarin was 0.74 (95% CI, 0.49 - 1.12).</p><p>The incidence rates for the principal safety outcome (major and non-major clinically relevant bleeding events) were similar for both treatment groups (Table 5).</p><p>Table 4: Efficacy results from phase III ROCKET AF</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Study population</strong></p></td><td colspan="3"><p><strong>ITT analyses of efficacy in patients with non-valvular atrial fibrillation</strong></p></td></tr><tr><td><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Treatment dose</strong></p></td><td><p><strong>Rivaroxaban 20 mg od</strong></p><p><strong>(15 mg od in patients with moderate renal impairment)</strong></p><p><strong>Event rate (100 pt-yr)</strong></p></td><td><p><strong>Warfarin titrated to a target</strong></p><p><strong>INR of 2.5 (therapeutic range 2.0 to 3.0)</strong></p><p><strong>Event rate (100 pt-yr)</strong></p></td><td><p><strong>&nbsp;</strong></p><p><strong>HR (95% CI)</strong></p><p><strong>p-value, test for superiority</strong></p></td></tr><tr><td><p>Stroke and non-CNS systemic embolism</p></td><td><p>269</p><p>(2.12)</p></td><td><p>306</p><p>(2.42)</p></td><td><p>0.88</p><p>(0.74 - 1.03)</p><p>0.117</p></td></tr><tr><td><p>Stroke, non-CNS systemic</p><p>embolism and vascular death</p></td><td><p>572</p><p>(4.51)</p></td><td><p>609</p><p>(4.81)</p></td><td><p>0.94</p><p>(0.84 - 1.05)</p><p>0.265</p></td></tr><tr><td><p>Stroke, non-CNS systemic</p><p>embolism, vascular death and myocardial infarction</p></td><td><p>659</p><p>(5.24)</p></td><td><p>709</p><p>(5.65)</p></td><td><p>0.93</p><p>(0.83 - 1.03)</p><p>0.158</p></td></tr><tr><td><p>Stroke</p></td><td><p>253</p><p>(1.99)</p></td><td><p>281</p><p>(2.22)</p></td><td><p>0.90</p><p>(0.76 - 1.07)</p><p>0.221</p></td></tr><tr><td><p>Non-CNS systemic embolism</p></td><td><p>20</p><p>(0.16)</p></td><td><p>27</p><p>(0.21)</p></td><td><p>0.74</p><p>(0.42 - 1.32)</p><p>0.308</p></td></tr><tr><td><p>Myocardial infarction</p></td><td><p>130</p><p>(1.02)</p></td><td><p>142</p><p>(1.11)</p></td><td><p>0.91</p><p>(0.72 - 1.16)</p><p>0.464</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Table 5: Safety results from phase III ROCKET AF</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Study population</strong></p></td><td colspan="4"><p><strong>Patients with non-valvular atrial fibrillation<sup>a)</sup></strong></p></td></tr><tr><td><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Treatment dose</strong></p></td><td><p><strong>Rivaroxaban 20 mg once a day</strong></p><p><strong>(15 mg once a day in patients with moderate renal impairment)</strong></p><p><strong>Event rate (100 pt-yr)</strong></p></td><td><p><strong>Warfarin titrated to a target</strong></p><p><strong>INR of 2.5</strong></p><p><strong>(therapeutic range 2.0</strong></p><p><strong>to 3.0)</strong></p><p><strong>Event rate (100 pt-yr)</strong></p></td><td colspan="2"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>HR (95% CI)</strong></p><p><strong>p-value</strong></p></td></tr><tr><td><p>Major and non-major</p><p>clinically relevant bleeding events</p></td><td><p>1,475</p><p>(14.91)</p></td><td><p>1,449</p><p>(14.52)</p></td><td colspan="2"><p>1.03 (0.96 - 1.11)</p><p>0.442</p></td></tr><tr><td rowspan="2"><p>Major bleeding events</p></td><td><p>395</p></td><td><p>386</p></td><td colspan="2"><p>1.04 (0.90 - 1.20)</p></td></tr><tr><td><p>(3.60)</p></td><td><p>(3.45)</p></td><td colspan="2"><p>0.576</p></td></tr><tr><td rowspan="2"><p>Death due to bleeding*</p></td><td><p>27</p></td><td><p>55</p></td><td colspan="2"><p>0.50 (0.31 - 0.79)</p></td></tr><tr><td><p>(0.24)</p></td><td><p>(0.48)</p></td><td colspan="2"><p>0.003</p></td></tr><tr><td rowspan="2"><p>Critical organ bleeding*</p></td><td><p>91</p></td><td><p>133</p></td><td colspan="2"><p>0.69 (0.53 - 0.91)</p></td></tr><tr><td><p>(0.82)</p></td><td><p>(1.18)</p></td><td colspan="2"><p>0.007</p></td></tr><tr><td><p>Intracranial</p></td><td><p>55</p></td><td><p>84</p></td><td colspan="2"><p>0.67 (0.47 - 0.93)</p></td></tr><tr><td><p>haemorrhage*</p></td><td><p>(0.49)</p></td><td><p>(0.74)</p></td><td colspan="2"><p>0.019</p></td></tr><tr><td rowspan="2"><p>Haemoglobin drop*</p></td><td><p>305</p></td><td><p>254</p></td><td colspan="2"><p>1.22 (1.03 - 1.44)</p></td></tr><tr><td><p>(2.77)</p></td><td><p>(2.26)</p></td><td colspan="2"><p>0.019</p></td></tr><tr><td><p>Transfusion of 2 or more</p><p>units of packed red blood cells or whole blood*</p></td><td><p>183</p><p>(1.65)</p></td><td><p>149</p><p>(1.32)</p></td><td colspan="2"><p>1.25 (1.01 - 1.55)</p><p>0.044</p></td></tr><tr><td><p>Non-major clinically</p></td><td><p>1,185</p></td><td><p>1,151</p></td><td colspan="2"><p>1.04 (0.96 - 1.13)</p></td></tr><tr><td><p>relevant bleeding events</p></td><td><p>(11.80)</p></td><td><p>(11.37)</p></td><td colspan="2"><p>0.345</p></td></tr><tr><td rowspan="2"><p>All-cause mortality</p></td><td><p>208</p></td><td><p>250</p></td><td colspan="2"><p>0.85 (0.70 - 1.02)</p></td></tr><tr><td><p>(1.87)</p></td><td><p>(2.21)</p></td><td colspan="2"><p>0.073</p></td></tr><tr><td colspan="4"><p>a) Safety population, on treatment</p><p>* Nominally significant</p></td><td><p>&nbsp;</p></td></tr></tbody></table><p>In addition to the phase III ROCKET AF study, a prospective, single-arm, post-authorization, non- interventional, open-label cohort study (XANTUS) with central outcome adjudication including thromboembolic events and major bleeding has been conducted. 6,785 patients with non-valvular atrial fibrillation were enrolled for prevention of stroke and non-central nervous system (CNS) systemic embolism in clinical practice. The mean CHADS2 and HAS-BLED scores were both 2.0 in XANTUS, compared to a mean CHADS2 and HAS-BLED score of 3.5 and 2.8 in ROCKET AF, respectively. Major bleeding occurred in 2.1 per 100 patient years. Fatal haemorrhage was reported in 0.2 per 100 patient years and intracranial haemorrhage in 0.4 per 100 patient years. Stroke or non-CNS systemic embolism was recorded in 0.8 per 100 patient years.</p><p>These observations in clinical practice are consistent with the established safety profile in this indication.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Patients undergoing cardioversion</u></p><p>A prospective, randomised, open-label, multicentre, exploratory study with blinded endpoint evaluation (X-VERT) was conducted in 1504 patients (oral anticoagulant naive and pre-treated) with non-valvular atrial fibrillation scheduled for cardioversion to compare Rivaroxaban with dose-adjusted VKA (randomised 2:1), for the prevention of cardiovascular events. TEE- guided (1 - 5 days of pre-treatment) or conventional cardioversion (at least three weeks of pre-treatment) strategies were employed. The primary efficacy outcome (all stroke, transient ischaemic attack, non-CNS systemic embolism, myocardial infarction (MI) and cardiovascular death) occurred in 5 (0.5%) patients in the Rivaroxaban group (n = 978) and 5 (1.0%) patients in the VKA group (n = 492; RR 0.50; 95% CI 0.15-1.73; modified ITT population). The principal safety outcome (major bleeding) occurred in 6 (0.6%) and 4 (0.8%) patients in the Rivaroxaban (n = 988) and VKA (n = 499) groups, respectively (RR 0.76; 95 % CI 0.21- 2.67; safety population). This exploratory study showed comparable efficacy and safety between Rivaroxaban and VKA treatment groups in the setting of cardioversion.</p><p><u>Patients with non-valvular atrial fibrillation who undergo PCI with stent placement</u></p><p>A randomised, open-label, multicentre study (PIONEER AF-PCI) was conducted in 2,124 patients with non-valvular atrial fibrillation who underwent PCI with stent placement for primary atherosclerotic disease to compare safety of two Rivaroxaban regimens and one VKA regimen. Patients were randomly assigned in a 1:1:1 fashion for an overall 12-month-therapy. Patients with a history of stroke or TIA were excluded.</p><p>Group 1 received Rivaroxaban 15 mg once daily (10 mg once daily in patients with creatinine clearance 30 - 49 ml/min) plus P2Y12 inhibitor. Group 2 received Rivaroxaban 2.5 mg twice daily plus DAPT (dual antiplatelet therapy i.e. clopidogrel 75 mg [or alternate P2Y12 inhibitor] plus low-dose acetylsalicylic acid [ASA]) for 1, 6 or 12 months followed by Rivaroxaban 15 mg (or 10 mg for subjects with creatinine clearance 30 - 49 ml/min) once daily plus low-dose ASA. Group 3 received dose- adjusted VKA plus DAPT for 1, 6 or 12 months followed by dose-adjusted VKA plus low-dose ASA.</p><p>The primary safety endpoint, clinically significant bleeding events, occurred in 109 (15.7%), 117 (16.6%), and 167 (24.0%) subjects in group 1, group 2 and group 3, respectively (HR 0.59; 95% CI 0.47-0.76; p&lt;0.001, and HR 0.63; 95% CI 0.50-0.80; p&lt;0.001, respectively). The secondary endpoint (composite of cardiovascular events CV death, MI, or stroke) occurred in 41 (5.9%), 36 (5.1%), and 36 (5.2%) subjects in the group 1, group 2 and group 3, respectively. Each of the Rivaroxaban regimens showed a significant reduction in clinically significant bleeding events compared to the VKA regimen in patients with non-valvular atrial fibrillation who underwent a PCI with stent placement.</p><p>The primary objective of PIONEER AF-PCI was to assess safety. Data on efficacy (including thromboembolic events) in this population are limited.</p><p>&nbsp;</p><p><em>Treatment of DVT, PE and prevention of recurrent DVT and PE</em></p><p>The Rivaroxaban clinical programme was designed to demonstrate the efficacy of Rivaroxaban in the initial and continued treatment of acute DVT and PE and prevention of recurrence.</p><p>Over 12,800 patients were studied in four randomised controlled phase III clinical studies (Einstein DVT, Einstein PE, Einstein Extension and Einstein Choice) and additionally a predefined pooled analysis of the Einstein DVT and Einstein PE studies was conducted. The overall combined treatment duration in all studies was up to 21 months.</p><p>In Einstein DVT 3,449 patients with acute DVT were studied for the treatment of DVT and the prevention of recurrent DVT and PE (patients who presented with symptomatic PE were excluded from this study). The treatment duration was for 3, 6 or 12 months depending on the clinical judgement of the investigator.</p><p>For the initial 3 week treatment of acute DVT 15 mg Rivaroxaban was administered twice daily. This was followed by 20 mg Rivaroxaban once daily.</p><p>In Einstein PE, 4,832 patients with acute PE were studied for the treatment of PE and the prevention of recurrent DVT and PE. The treatment duration was for 3, 6 or 12 months depending on the clinical judgement of the investigator.</p><p>For the initial treatment of acute PE 15 mg Rivaroxaban was administered twice daily for three weeks. This was followed by 20 mg Rivaroxaban once daily.</p><p>In both the Einstein DVT and the Einstein PE study, the comparator treatment regimen consisted of enoxaparin administered for at least 5 days in combination with vitamin K antagonist treatment until the PT/INR was in therapeutic range (&ge; 2.0). Treatment was continued with a vitamin K antagonist dose-adjusted to maintain the PT/INR values within the therapeutic range of 2.0 to 3.0.</p><p>&nbsp;</p><p>In Einstein Extension 1,197 patients with DVT or PE were studied for the prevention of recurrent DVT and PE. The treatment duration was for an additional 6 or 12 months in patients who had completed 6 to 12 months of treatment for venous thromboembolism depending on the clinical judgment of the investigator. Rivaroxaban 20 mg once daily was compared with placebo.</p><p>Einstein DVT, PE and Extension used the same pre-defined primary and secondary efficacy outcomes. The primary efficacy outcome was symptomatic recurrent VTE defined as the composite of recurrent DVT or fatal or non-fatal PE. The secondary efficacy outcome was defined as the composite of recurrent DVT, non-fatal PE and all-cause mortality.</p><p>In Einstein Choice, 3,396 patients with confirmed symptomatic DVT and/or PE who completed 6-12 months of anticoagulant treatment were studied for the prevention of fatal PE or non-fatal symptomatic recurrent DVT or PE. Patients with an indication for continued therapeutic-dosed anticoagulation were excluded from the study. The treatment duration was up to 12 months depending on the individual randomisation date (median: 351 days). Rivaroxaban 20 mg once daily and Rivaroxaban 10 mg once daily were compared with 100 mg acetylsalicylic acid once daily.</p><p>The primary efficacy outcome was symptomatic recurrent VTE defined as the composite of recurrent DVT or fatal or non-fatal PE.</p><p>In the Einstein DVT study (Table 6) Rivaroxaban was demonstrated to be non-inferior to enoxaparin/VKA for the primary efficacy outcome (p &lt; 0.0001 (test for non-inferiority); HR: 0.680 (0.443 - 1.042), p=0.076 (test for superiority)). The prespecified net clinical benefit (primary efficacy outcome plus major bleeding events) was reported with a HR of 0.67 ((95% CI: 0.47 - 0.95), nominal p value p=0.027) in favour of Rivaroxaban. INR values were within the therapeutic range a mean of 60.3% of the time for the mean treatment duration of 189 days, and 55.4%, 60.1%, and 62.8% of the time in the 3-, 6-, and 12-month intended treatment duration groups, respectively. In the enoxaparin/VKA group, there was no clear relation between the level of mean centre TTR (Time in Target INR Range of 2.0 - 3.0) in the equally sized tertiles and the incidence of the recurrent VTE (P=0.932 for interaction). Within the highest tertile according to centre, the HR with Rivaroxaban versus warfarin was 0.69 (95% CI: 0.35 - 1.35).</p><p>The incidence rates for the primary safety outcome (major or clinically relevant non-major bleeding events) as well as the secondary safety outcome (major bleeding events) were similar for both treatment groups.</p><p>Table 6: Efficacy and safety results from phase III Einstein DVT</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Study population</strong></p></td><td colspan="2"><p><strong>3,449 patients with symptomatic acute deep vein thrombosis</strong></p></td></tr><tr><td><p><strong>Treatment dose and duration</strong></p></td><td><p><strong>Rivaroxaban<sup>a)</sup> 3, 6 or 12 months</strong></p><p><strong>N=1,731</strong></p></td><td><p><strong>Enoxaparin/VKA<sup>b)</sup> 3, 6 or 12 months N=1,718</strong></p></td></tr><tr><td rowspan="2"><p>Symptomatic recurrent VTE*</p></td><td><p>36</p></td><td><p>51</p></td></tr><tr><td><p>(2.1%)</p></td><td><p>(3.0%)</p></td></tr><tr><td rowspan="2"><p>Symptomatic recurrent PE</p></td><td><p>20</p></td><td><p>18</p></td></tr><tr><td><p>(1.2%)</p></td><td><p>(1.0%)</p></td></tr><tr><td rowspan="2"><p>Symptomatic recurrent DVT</p></td><td><p>14</p></td><td><p>28</p></td></tr><tr><td><p>(0.8%)</p></td><td><p>(1.6%)</p></td></tr><tr><td><p>Symptomatic PE and DVT</p></td><td><p>1</p><p>(0.1%)</p></td><td><p>0</p></td></tr><tr><td><p>Fatal PE/death where PE cannot</p></td><td><p>4</p></td><td><p>6</p></td></tr><tr><td><p>be ruled out</p></td><td><p>(0.2%)</p></td><td><p>(0.3%)</p></td></tr><tr><td><p>Major or clinically relevant non-</p></td><td><p>139</p></td><td><p>138</p></td></tr><tr><td><p>major bleeding</p></td><td><p>(8.1%)</p></td><td><p>(8.1%)</p></td></tr><tr><td rowspan="2"><p>Major bleeding events</p></td><td><p>14</p></td><td><p>20</p></td></tr><tr><td><p>(0.8%)</p></td><td><p>(1.2%)</p></td></tr><tr><td colspan="3"><p>a)&nbsp; Rivaroxaban 15 mg twice daily for 3 weeks followed by 20 mg once daily</p><p>b)&nbsp; Enoxaparin for at least 5 days, overlapped with and followed by VKA</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>* </strong>p &lt; 0.0001 (non-inferiority to a prespecified HR of 2.0); HR: 0.680 (0.443 - 1.042), p=0.076 (superiority)</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>In the Einstein PE study (Table 7) Rivaroxaban was demonstrated to be non-inferior to enoxaparin/VKA for the primary efficacy outcome (p=0.0026 (test for non-inferiority); HR: 1.123 (0.749 - 1.684)). The prespecified net clinical benefit (primary efficacy outcome plus major bleeding events) was reported with a HR of 0.849 ((95% CI: 0.633 - 1.139), nominal p value p= 0.275). INR values were within the therapeutic range a mean of 63% of the time for the mean treatment duration of 215 days, and 57%, 62%, and 65% of the time in the 3-, 6-, and 12-month intended treatment duration groups, respectively. In the enoxaparin/VKA group, there was no clear relation between the level of mean centre TTR (Time in Target INR Range of 2.0 - 3.0) in the equally sized tertiles and the incidence of the recurrent VTE (p=0.082 for interaction). Within the highest tertile according to centre, the HR with Rivaroxaban versus warfarin was 0.642 (95% CI: 0.277 - 1.484).</p><p>The incidence rates for the primary safety outcome (major or clinically relevant non-major bleeding events) were slightly lower in the Rivaroxaban treatment group (10.3% (249/2412)) than in the enoxaparin/VKA treatment group (11.4% (274/2405)). The incidence of the secondary safety outcome (major bleeding events) was lower in the Rivaroxaban group (1.1% (26/2412)) than in the enoxaparin/VKA group (2.2% (52/2405)) with a HR 0.493 (95% CI: 0.308 - 0.789).</p><p>Table 7: Efficacy and safety results from phase III Einstein PE</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Study population</strong></p></td><td colspan="2"><p><strong>4,832 patients with an acute symptomatic PE</strong></p></td></tr><tr><td><p><strong>Treatment dose and duration</strong></p></td><td><p><strong>Rivaroxaban<sup>a)</sup> 3, 6 or 12 months</strong></p><p><strong>N=2,419</strong></p></td><td><p><strong>Enoxaparin/VKA<sup>b)</sup></strong></p><p><strong>3, 6 or 12 months N=2,413</strong></p></td></tr><tr><td rowspan="2"><p>Symptomatic recurrent VTE*</p></td><td><p>50</p></td><td><p>44</p></td></tr><tr><td><p>(2.1%)</p></td><td><p>(1.8%)</p></td></tr><tr><td rowspan="2"><p>Symptomatic recurrent PE</p></td><td><p>23</p></td><td><p>20</p></td></tr><tr><td><p>(1.0%)</p></td><td><p>(0.8%)</p></td></tr><tr><td rowspan="2"><p>Symptomatic recurrent DVT</p></td><td><p>18</p></td><td><p>17</p></td></tr><tr><td><p>(0.7%)</p></td><td><p>(0.7%)</p></td></tr><tr><td><p>Symptomatic PE and DVT</p></td><td><p>0</p></td><td><p>2</p><p>(&lt;0.1%)</p></td></tr><tr><td><p>Fatal PE/death where PE cannot</p></td><td><p>11</p></td><td><p>7</p></td></tr><tr><td><p>be ruled out</p></td><td><p>(0.5%)</p></td><td><p>(0.3%)</p></td></tr><tr><td><p>Major or clinically relevant non-</p></td><td><p>249</p></td><td><p>274</p></td></tr><tr><td><p>major bleeding</p></td><td><p>(10.3%)</p></td><td><p>(11.4%)</p></td></tr><tr><td rowspan="2"><p>Major bleeding events</p></td><td><p>26</p></td><td><p>52</p></td></tr><tr><td><p>(1.1%)</p></td><td><p>(2.2%)</p></td></tr><tr><td colspan="3"><p>a)&nbsp; Rivaroxaban 15 mg twice daily for 3 weeks followed by 20 mg once daily</p><p>b)&nbsp; Enoxaparin for at least 5 days, overlapped with and followed by VKA</p><p>* p &lt; 0.0026 (non-inferiority to a prespecified HR of 2.0); HR: 1.123 (0.749 - 1.684)</p></td></tr></tbody></table><p>A prespecified pooled analysis of the outcome of the Einstein DVT and PE studies was conducted (Table 8).</p><p>&nbsp;</p><p>Table 8: Efficacy and safety results from pooled analysis of phase III Einstein DVT and Einstein PE<strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Study population</strong></p></td><td colspan="2"><p><strong>8,281 patients with an acute symptomatic DVT or PE</strong></p></td></tr><tr><td><p><strong>Treatment dose and duration</strong></p></td><td><p><strong>Rivaroxaban<sup>a)</sup> 3, 6 or 12 months</strong></p><p><strong>N=4,150</strong></p></td><td><p><strong>Enoxaparin/VKA<sup>b)</sup></strong></p><p><strong>3, 6 or 12 months N=4,131</strong></p></td></tr><tr><td rowspan="2"><p>Symptomatic recurrent VTE*</p></td><td><p>86</p></td><td><p>95</p></td></tr><tr><td><p>(2.1%)</p></td><td><p>(2.3%)</p></td></tr><tr><td rowspan="2"><p>Symptomatic recurrent PE</p></td><td><p>43</p></td><td><p>38</p></td></tr><tr><td><p>(1.0%)</p></td><td><p>(0.9%)</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="width:184px"><p>Symptomatic recurrent DVT</p></td><td style="width:194px"><p>32</p></td><td style="width:159px"><p>45</p></td></tr><tr><td style="width:194px"><p>(0.8%)</p></td><td style="width:159px"><p>(1.1%)</p></td></tr><tr><td rowspan="2" style="width:184px"><p>Symptomatic PE and DVT</p></td><td style="width:194px"><p>1</p></td><td style="width:159px"><p>2</p></td></tr><tr><td style="width:194px"><p>(&lt;0.1%)</p></td><td style="width:159px"><p>(&lt;0.1%)</p></td></tr><tr><td style="width:184px"><p>Fatal PE/death where PE cannot</p></td><td style="width:194px"><p>15</p></td><td style="width:159px"><p>13</p></td></tr><tr><td style="width:184px"><p>be ruled out</p></td><td style="width:194px"><p>(0.4%)</p></td><td style="width:159px"><p>(0.3%)</p></td></tr><tr><td style="width:184px"><p>Major or clinically relevant non-</p></td><td style="width:194px"><p>388</p></td><td style="width:159px"><p>412</p></td></tr><tr><td style="width:184px"><p>major bleeding</p></td><td style="width:194px"><p>(9.4%)</p></td><td style="width:159px"><p>(10.0%)</p></td></tr><tr><td rowspan="2" style="width:184px"><p>Major bleeding events</p></td><td style="width:194px"><p>40</p></td><td style="width:159px"><p>72</p></td></tr><tr><td style="width:194px"><p>(1.0%)</p></td><td style="width:159px"><p>(1.7%)</p></td></tr><tr><td colspan="3"><p>a)&nbsp; Rivaroxaban 15 mg twice daily for 3 weeks followed by 20 mg once daily</p><p>b)&nbsp; Enoxaparin for at least 5 days, overlapped with and followed by VKA</p><p><strong>* </strong>p &lt; 0.0001 (non-inferiority to a prespecified HR of 1.75); HR: 0.886 (0.661 - 1.186)</p></td></tr></tbody></table><p>The pre-specified net clinical benefit (primary efficacy outcome plus major bleeding events) of the pooled analysis was reported with a HR of 0.771 ((95% CI: 0.614 - 0.967), nominal p value p = 0.0244).</p><p>In the Einstein Extension study (Table 9) Rivaroxaban was superior to placebo for the primary and secondary efficacy outcomes. For the primary safety outcome (major bleeding events) there was a non- significant numerically higher incidence rate for patients treated with Rivaroxaban 20 mg once daily compared to placebo. The secondary safety outcome (major or clinically relevant non-major bleeding events) showed higher rates for patients treated with Rivaroxaban 20 mg once daily compared to placebo.</p><p>Table 9: Efficacy and safety results from phase III Einstein Extension</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Study population</strong></p></td><td colspan="2"><p><strong>1,197 patients continued treatment and prevention of recurrent venous thromboembolism</strong></p></td></tr><tr><td><p><strong>Treatment dose and duration</strong></p></td><td><p><strong>Rivaroxaban<sup>a)</sup></strong></p><p><strong>6 or 12 months N=602</strong></p></td><td><p><strong>Placebo</strong></p><p><strong>6 or 12 months N=594</strong></p></td></tr><tr><td rowspan="2"><p>Symptomatic recurrent VTE*</p></td><td><p>8</p></td><td><p>42</p></td></tr><tr><td><p>(1.3%)</p></td><td><p>(7.1%)</p></td></tr><tr><td rowspan="2"><p>Symptomatic recurrent PE</p></td><td><p>2</p></td><td><p>13</p></td></tr><tr><td><p>(0.3%)</p></td><td><p>(2.2%)</p></td></tr><tr><td rowspan="2"><p>Symptomatic recurrent DVT</p></td><td><p>5</p></td><td><p>31</p></td></tr><tr><td><p>(0.8%)</p></td><td><p>(5.2%)</p></td></tr><tr><td><p>Fatal PE/death where PE cannot</p></td><td><p>1</p></td><td><p>1</p></td></tr><tr><td><p>be ruled out</p></td><td><p>(0.2%)</p></td><td><p>(0.2%)</p></td></tr><tr><td rowspan="2"><p>Major bleeding events</p></td><td><p>4</p></td><td><p>0</p></td></tr><tr><td><p>(0.7%)</p></td><td><p>(0.0%)</p></td></tr><tr><td><p>Clinically relevant non-major</p></td><td><p>32</p></td><td><p>7</p></td></tr><tr><td><p>bleeding</p></td><td><p>(5.4%)</p></td><td><p>(1.2%)</p></td></tr><tr><td colspan="3"><p>a) Rivaroxaban 20 mg once daily</p><p><strong>* </strong>p &lt; 0.0001 (superiority), HR: 0.185 (0.087 - 0.393)</p></td></tr></tbody></table><p>In the Einstein Choice study (Table 10) Rivaroxaban 20 mg and 10 mg were both superior to 100 mg acetylsalicylic acid for the primary efficacy outcome. The principal safety outcome (major bleeding events) was similar for patients treated with Rivaroxaban 20 mg and 10 mg once daily compared to 100 mg acetylsalicylic acid.</p><p>Table 10: Efficacy and safety results from phase III Einstein Choice</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="width:418px"><p><strong>Study population</strong></p></td><td colspan="3" style="width:369px"><p><strong>3,396 patients continued prevention of recurrent venous thromboembolism</strong></p></td></tr><tr><td style="width:418px"><p><strong>Treatment dose</strong></p></td><td style="width:119px"><p><strong>Rivaroxaban 20 mg od</strong></p><p><strong>N=1,107</strong></p></td><td style="width:133px"><p><strong>Rivaroxaban 10 mg od</strong></p><p><strong>N=1,127</strong></p></td><td style="width:129px"><p><strong>ASA 100 mg od N=1,131</strong></p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Treatment duration median [interquartile range]</p></td><td><p>349 [189-362] days</p></td><td style="width:128px"><p>353 [190-362] days</p></td><td style="width:130px"><p>350 [186-362]</p><p>days</p></td></tr><tr><td><p>Symptomatic recurrent VTE</p></td><td><p>17 (1.5%)*</p></td><td style="width:128px"><p>13</p><p>(1.2%)**</p></td><td style="width:130px"><p>50</p><p>(4.4%)</p></td></tr><tr><td><p>Symptomatic recurrent PE</p></td><td><p>6</p><p>(0.5%)</p></td><td style="width:128px"><p>6</p><p>(0.5%)</p></td><td style="width:130px"><p>19</p><p>(1.7%)</p></td></tr><tr><td><p>Symptomatic recurrent DVT</p></td><td><p>9</p><p>(0.8%)</p></td><td style="width:128px"><p>8</p><p>(0.7%)</p></td><td style="width:130px"><p>30</p><p>(2.7%)</p></td></tr><tr><td><p>Fatal PE/death where PE cannot be ruled out</p></td><td><p>2</p><p>(0.2%)</p></td><td style="width:128px"><p>0</p><p>(0.0%)</p></td><td style="width:130px"><p>2</p><p>(0.2%)</p></td></tr><tr><td><p>Symptomatic recurrent VTE, MI, stroke, or non- CNS systemic embolism</p></td><td><p>19</p><p>(1.7%)</p></td><td style="width:128px"><p>18</p><p>(1.6%)</p></td><td style="width:130px"><p>56</p><p>(5.0%)</p></td></tr><tr><td><p>Major bleeding events</p></td><td><p>6</p><p>(0.5%)</p></td><td style="width:128px"><p>5</p><p>(0.4%)</p></td><td style="width:130px"><p>3</p><p>(0.3%)</p></td></tr><tr><td><p>Clinically relevant non- major bleeding</p></td><td><p>30</p><p>(2.7)</p></td><td style="width:128px"><p>22</p><p>(2.0)</p></td><td style="width:130px"><p>20</p><p>(1.8)</p></td></tr><tr><td><p>Symptomatic recurrent</p><p>VTE or major bleeding (net clinical benefit)</p></td><td><p>23</p><p>(2.1%)<sup>+</sup></p></td><td style="width:128px"><p>17</p><p>(1.5%)<sup>++</sup></p></td><td style="width:130px"><p>53</p><p>(4.7%)</p></td></tr><tr><td colspan="4"><p>* p&lt;0.001(superiority) Rivaroxaban 20 mg od vs ASA 100 mg od; HR=0.34 (0.20-0.59)</p><p>** p&lt;0.001 (superiority) Rivaroxaban 10 mg od vs ASA 100 mg od; HR=0.26 (0.14-0.47)</p><p><sup>+</sup> Rivaroxaban 20 mg od vs. ASA 100 mg od; HR=0.44 (0.27-0.71), p=0.0009 (nominal)</p><p><sup>++</sup> Rivaroxaban 10 mg od vs. ASA 100 mg od; HR=0.32 (0.18-0.55), p&lt;0.0001 (nominal)</p></td></tr></tbody></table><p>In addition to the phase III EINSTEIN programme, a prospective, non-interventional, open-label cohort study (XALIA) with central outcome adjudication including recurrent VTE, major bleeding and death has been conducted. 5,142 patients with acute DVT were enrolled to investigate the long-term safety of Rivaroxaban compared with standard-of-care anticoagulation therapy in clinical practice. Rates of major bleeding, recurrent VTE and all-cause mortality for Rivaroxaban were 0.7%, 1.4% and 0.5%, respectively. There were differences in patient baseline characteristics including age, cancer and renal impairment. A pre-specified propensity score stratified analysis was used to adjust for measured baseline differences but residual confounding may, in spite of this, influence the results. AdjustedHRs comparing Rivaroxaban and standard-of-care for major bleeding, recurrent VTE and all-cause mortality were 0.77 (95% CI 0.40 - 1.50), 0.91 (95% CI 0.54 - 1.54) and 0.51 (95% CI 0.24 - 1.07), respectively.</p><p>These results in clinical practice are consistent with the established safety profile in this indication.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p><u>Treatment of VTE and prevention of VTE recurrence in paediatric patients</u></p><p>A total of 727 children with confirmed acute VTE, of whom 528 received rivaroxaban, were studied in 6 open-label, multicentre paediatric studies. Body weight-adjusted dosing in patients from birth to less than 18 years resulted in rivaroxaban exposure similar to that observed in adult DVT patients treated with rivaroxaban 20 mg once daily as confirmed in the phase III study (see section 5.2).</p><p>The EINSTEIN Junior phase III study was a randomised, active-controlled, open-label multicentre clinical study in 500 paediatric patients (aged from birth to &lt; 18 years) with confirmed acute VTE. There were 276 children aged 12 to &lt; 18 years, 101 children aged 6 to &lt; 12 years, 69 children aged 2 to &lt; 6 years, and 54 children aged &lt; 2 years.</p><p>Index VTE was classified as either central venous catheter-related VTE (CVC-VTE; 90/335 patients in the rivaroxaban group, 37/165 patients in the comparator group), cerebral vein and sinus thrombosis (CVST; 74/335 patients in the rivaroxaban group, 43/165 patients in the comparator group), and all others including DVT and PE (non-CVC-VTE; 171/335 patients in the rivaroxaban group, 84/165 patients in the comparator group). The most common presentation of index thrombosis in children aged 12 to &lt; 18 years was non-CVC-VTE in 211 (76.4%); in children aged 6 to &lt; 12 years and aged 2 to &lt; 6 years was CVST in 48 (47.5%) and 35 (50.7%), respectively; and in children aged &lt; 2 years was CVC-VTE in 37 (68.5%).</p><p>&nbsp;</p><p>There were no children &lt; 6 months with CVST in the rivaroxaban group. 22 of the patients with CVST had a CNS infection (13 patients in the rivaroxaban group and 9 patients in comparator group).</p><p>VTE was provoked by persistent, transient, or both persistent and transient risk factors in 438 (87.6%) children.</p><p>Patients received initial treatment with therapeutic doses of UFH, LMWH, or fondaparinux for at least 5 days, and were randomised 2:1 to receive either body weight-adjusted doses of rivaroxaban or comparator group (heparins, VKA) for a main study treatment period of 3 months (1 month for children &lt; 2 years with CVC-VTE). At the end of the main study treatment period, the diagnostic imaging test, which was obtained at baseline, was repeated, if clinically feasible. The study treatment could be stopped at this point, or at the discretion of the Investigator continued for up to 12 months (for children &lt; 2 years with CVC-VTE up to 3 months) in total.</p><p>The primary efficacy outcome was symptomatic recurrent VTE. The primary safety outcome was the composite of major bleeding and clinically relevant non-major bleeding (CRNMB). All efficacy and safety outcomes were centrally adjudicated by an independent committee blinded for treatment allocation. The efficacy and safety results are shown in Tables 11 and 12 below.</p><p>Recurrent VTEs occurred in the rivaroxaban group in 4 of 335 patients and in the comparator group in 5 of 165 patients. The composite of major bleeding and CRNMB was reported in 10 of 329 patients (3%) treated with rivaroxaban and in 3 of 162 patients (1.9%) treated with comparator. Net clinical benefit (symptomatic recurrent VTE plus major bleeding events) was reported in the rivaroxaban group in 4 of 335 patients and in the comparator group in 7 of 165 patients. Normalisation of the thrombus burden on repeat imaging occurred in 128 of 335 patients with rivaroxaban treatment and in 43 of 165 patients in the comparator group. These findings were generally similar among age groups. There were 119 (36.2%) children with any treatment-emergent bleeding in the rivaroxaban group and 45 (27.8%) children in the comparator group.</p><p>Table 11: Efficacy results at the end of the main treatment period</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Event</p></td><td><p>Rivaroxaban N=335*</p></td><td><p>Comparator N=165*</p></td></tr><tr><td><p>Recurrent VTE (primary efficacy outcome)</p></td><td><p>4</p><p>(1.2%, 95% CI 0.4% &ndash;</p><p>3.0%)</p></td><td><p>5</p><p>(3.0%, 95% CI 1.2% -</p><p>6.6%)</p></td></tr><tr><td><p>Composite: Symptomatic recurrent VTE + asymptomatic deterioration on repeat imaging</p></td><td><p>5</p><p>(1.5%, 95% CI 0.6% &ndash;</p><p>3.4%)</p></td><td><p>6</p><p>(3.6%, 95% CI 1.6% &ndash;</p><p>7.6%)</p></td></tr><tr><td><p>Composite: Symptomatic recurrent VTE + asymptomatic deterioration + no change on repeat imaging</p></td><td><p>21</p><p>(6.3%, 95% CI 4.0% &ndash;</p><p>9.2%)</p></td><td><p>19</p><p>(11.5%, 95% CI 7.3% &ndash;</p><p>17.4%)</p></td></tr><tr><td><p>Normalisation on repeat imaging</p></td><td><p>128</p><p>(38.2%, 95% CI 33.0% -</p><p>43.5%)</p></td><td><p>43</p><p>(26.1%, 95% CI 19.8% -</p><p>33.0%)</p></td></tr><tr><td><p>Composite: Symptomatic recurrent VTE + major bleeding (net clinical benefit)</p></td><td><p>4</p><p>(1.2%, 95% CI 0.4% -</p><p>3.0%)</p></td><td><p>7</p><p>(4.2%, 95% CI 2.0% -</p><p>8.4%)</p></td></tr><tr><td><p>Fatal or non-fatal pulmonary embolism</p></td><td><p>1</p><p>(0.3%, 95% CI 0.0% &ndash;</p><p>1.6%)</p></td><td><p>1</p><p>(0.6%, 95% CI 0.0% &ndash;</p><p>3.1%)</p></td></tr><tr><td colspan="3"><p>*FAS= full analysis set, all children who were randomised</p></td></tr></tbody></table><p><strong>&nbsp;&nbsp;</strong></p><p><!--[if gte vml 1]><o:wrapblock
 pagebreak="t">
 <v:group id="Group_x0020_26" o:spid="_x0000_s2050" style='position:absolute;
  margin-left:63.6pt;margin-top:13.6pt;width:471.4pt;height:19.8pt;z-index:-15725568;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' coordsize="59867,2514" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
  <v:shape id="Graphic_x0020_27" o:spid="_x0000_s2051" style='position:absolute;
   left:882;top:1628;width:57684;height:63;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="5768340,6350" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m5768340,l,,,6350r5768340,l5768340,xe" fillcolor="black" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="Graphic_x0020_28" o:spid="_x0000_s2052" style='position:absolute;
   width:59867;height:2514;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="5986780,251460" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m5986272,l,,,251459r5986272,l5986272,xe" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><w:wrap type="topAndBottom" anchorx="page"/>
 </v:group><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p><strong>Table 12: Safety results at the end of the main treatment period</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td><p>Rivaroxaban N=329*</p></td><td><p>Comparator N=162*</p></td></tr><tr><td><p>Composite: Major bleeding + CRNMB (primary safety outcome)</p></td><td><p>10</p><p>(3.0%, 95% CI 1.6% -</p><p>5.5%)</p></td><td><p>3</p><p>(1.9%, 95% CI 0.5% -</p><p>5.3%)</p></td></tr><tr><td><p>Major bleeding</p></td><td><p>0</p><p>(0.0%, 95% CI 0.0% -</p><p>1.1%)</p></td><td><p>2</p><p>(1.2%, 95% CI 0.2% -</p><p>4.3%)</p></td></tr><tr><td><p>Any treatment-emergent bleedings</p></td><td><p>119 (36.2%)</p></td><td><p>45 (27.8%)</p></td></tr><tr><td colspan="3"><p>* SAF= safety analysis set, all children who were randomised and received at least 1 dose of study medicinal product.</p></td></tr></tbody></table><p>The efficacy and safety profile of rivaroxaban was largely similar between the paediatric VTE population and the DVT/PE adult population, however, the proportion of subjects with any bleeding was higher in the paediatric VTE population as compared to the DVT/PE adult population.</p><p>&nbsp;</p><p><u>Patients with high risk triple positive anti-phospholipid syndrome</u></p><p>In an investigator sponsored, randomized open-label multicenter study with blinded endpoint adjudication, Rivaroxaban was compared to warfarin in patients with a history of thrombosis, diagnosed with anti-phospholipid syndrome and at high risk for thromboembolic events (positive for all 3 anti- phospholipid tests: lupus anticoagulant, anti-cardiolipin antibodies, and anti-beta 2-glycoprotein I antibodies). The trial was terminated prematurely after the enrolment of 120 patients due to an excess of events among patients in the Rivaroxaban arm. Mean follow-up was 569 days. 59 patients were randomized to Rivaroxaban 20 mg (15 mg for patients with creatinine clearance (CrCl) &lt;50 mL/min) and 61 to warfarin (INR 2.0-3.0). Thromboembolic events occurred in 12% of patients randomized to Rivaroxaban (4 ischaemic strokes and 3 myocardial infarctions). No events were reported in patients randomized to warfarin. Major bleeding occurred in 4 patients (7%) of the Rivaroxaban group and 2 patients (3%) of the warfarin group.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>The European Medicines Agency has waived the obligation to submit the results of studies with Rivaroxaban in all subsets of the paediatric population in the prevention of thromboembolic events (see section 4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>&nbsp;</p><p>The following information is based on the data obtained in adults.</p><p>Rivaroxaban is rapidly absorbed with maximum concentrations (Cmax) appearing 2 - 4 hours after tablet intake.</p><p>Oral absorption of Rivaroxaban is almost complete and oral bioavailability is high (80 - 100%) for the 10 mg tablet dose, irrespective of fasting/fed conditions. Intake with food does not affect Rivaroxaban AUC or Cmax at the 10 mg dose. Rivaroxaban 10 mg tablets can be taken with or without food</p><p>Due to a reduced extent of absorption an oral bioavailability of 66% was determined for the 20 mg tablet under fasting conditions. When Rivaroxaban 20 mg tablets are taken together with food increases in mean AUC by 39% were observed when compared to tablet intake under fasting conditions, indicating almost complete absorption and high oral bioavailability. Rivaroxaban 15 mg and 20 mg are to be taken with food (see section 4.2).</p><p>Rivaroxaban pharmacokinetics are approximately linear up to about 15 mg once daily in fasting state.</p><p>&nbsp;</p><p>Under fed conditions Rivaroxaban 10 mg, 15 mg and 20 mg tablets demonstrated dose-proportionality. At higher doses Rivaroxaban displays dissolution limited absorption with decreased bioavailability and decreased absorption rate with increased dose.</p><p>Variability in Rivaroxaban pharmacokinetics is moderate with inter-individual variability (CV%) ranging from 30% to 40%.</p><p>Absorption of Rivaroxaban is dependent on the site of its release in the gastrointestinal tract. A 29% and 56% decrease in AUC and Cmax compared to tablet was reported when Rivaroxaban granulate is released in the proximal small intestine. Exposure is further reduced when Rivaroxaban is released in the distal small intestine, or ascending colon. Therefore, administration of Rivaroxaban distal to the stomach should be avoided since this can result in reduced absorption and related Rivaroxaban exposure.</p><p>Bioavailability (AUC and Cmax) was comparable for 20 mg Rivaroxaban administered orally as a crushed tablet mixed in apple puree, or suspended in water and administered via a gastric tube followed by a liquid meal, compared to a whole tablet. Given the predictable, dose-proportional pharmacokinetic profile of Rivaroxaban, the bioavailability results from this study are likely applicable to lower Rivaroxaban doses.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>Children received rivaroxaban tablet or oral suspension during or closely after feeding or food intake and with a typical serving of liquid to ensure reliable dosing in children. As in adults, rivaroxaban is readily absorbed after oral administration as tablet or granules for oral suspension formulation in children. No difference in the absorption rate nor in the extent of absorption between the tablet and granules for oral suspension formulation was observed. No PK data following intravenous administration to children are available so that the absolute bioavailability of rivaroxaban in children is unknown. A decrease in the relative bioavailability for increasing doses (in mg/kg bodyweight) was found, suggesting absorption limitations for higher doses, even when taken together with food.</p><p>Rivaroxaban 20 mg tablets should be taken with feeding or with food (see section 4.2).</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Distribution</u></p><p>Plasma protein binding in humans is high at approximately 92% to 95%, with serum albumin being the main&nbsp;binding&nbsp;component.&nbsp;The volume&nbsp;of&nbsp;distribution&nbsp;is&nbsp;moderate&nbsp;with Vss being&nbsp;approximately 50&nbsp;litres.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>No data on rivaroxaban plasma protein binding specific to children is available. No PK data following intravenous administration of rivaroxaban to children is available. Vss estimated via population PK modelling in children (age range 0 to &lt; 18 years) following oral administration of rivaroxaban is dependent on body weight and can be described with an allometric function, with an average of 113 L for a subject with a body weight of 82.8 kg.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Biotransformation and elimination</u></p><p>Of the administered Rivaroxaban dose, approximately 2/3 undergoes metabolic degradation, with half then being eliminated renally and the other half eliminated by the faecal route. The final 1/3 of the administered dose undergoes direct renal excretion as unchanged active substance in the urine, mainly via active renal secretion.</p><p>Rivaroxaban is metabolised via CYP3A4, CYP2J2 and CYP-independent mechanisms. Oxidative degradation of the morpholinone moiety and hydrolysis of the amide bonds are the major sites of biotransformation. Based on <em>in vitro </em>investigations Rivaroxaban is a substrate of the transporter proteins P-gp (P-glycoprotein) and Bcrp (breast cancer resistance protein).</p><p>&nbsp;</p><p>Unchanged Rivaroxaban is the most important compound in human plasma, with no major or active circulating metabolites being present. With a systemic clearance of about 10 l/h, Rivaroxaban can be classified as a low-clearance substance. After intravenous administration of a 1 mg dose the elimination half-life is about 4.5 hours. After oral administration the elimination becomes absorption rate limited. Elimination of Rivaroxaban from plasma occurs with terminal half-lives of 5 to 9 hours in young individuals, and with terminal half-lives of 11 to 13 hours in the elderly.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>No metabolism data specific to children is available. No PK data following intravenous administration of rivaroxaban to children is available. CL estimated via population PK modelling in children (age range 0 to</p><p>&lt; 18 years) following oral administration of rivaroxaban is dependent on body weight and can be described with an allometric function, with an average of 8 L/h for a subject with body weight of 82.8 kg. The geometric mean values for disposition half-lives (t1/2) estimated via population PK modelling decrease with decreasing age and ranged from 4.2 h in adolescents to approximately 3 h in children aged 2-12 years down to 1.9 and 1.6 h in children aged 0.5-&lt; 2 years and less than 0.5 years, respectively.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Special populations</u></p><p><em>Gender</em></p><p>There were no clinically relevant differences in pharmacokinetics and pharmacodynamics between male and female patients. An exploratory analysis did not reveal relevant differences in rivaroxaban exposure between male and female children.</p><p>&nbsp;</p><p><em>Elderly population</em></p><p>Elderly patients exhibited higher plasma concentrations than younger patients, with mean AUC values being approximately 1.5 fold higher, mainly due to reduced (apparent) total and renal clearance. No dose adjustment is necessary.</p><p>&nbsp;</p><p><em>Different weight categories</em></p><p>Extremes in body weight (&lt; 50 kg or &gt; 120 kg) had only a small influence on Rivaroxaban plasma concentrations (less than 25%). No dose adjustment is necessary.</p><p>In children, rivaroxaban is dosed based on body weight. An exploratory analysis did not reveal a relevant impact of underweight or obesity on rivaroxaban exposure in children.</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Inter-ethnic differences</em></p><p>No clinically relevant inter-ethnic differences among Caucasian, African-American, Hispanic, Japanese or Chinese patients were observed regarding Rivaroxaban pharmacokinetics and pharmacodynamics.</p><p>&nbsp;</p><p>An exploratory analysis did not reveal relevant inter-ethnic differences in rivaroxaban exposure among Japanese, Chinese or Asian children outside Japan and China compared to the respective overall paediatric population.</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>Cirrhotic patients with mild hepatic impairment (classified as Child Pugh A) exhibited only minor changes in Rivaroxaban pharmacokinetics (1.2 fold increase in Rivaroxaban AUC on average), nearly comparable to their matched healthy control group. In cirrhotic patients with moderate hepatic</p><p>&nbsp;</p><p>impairment (classified as Child Pugh B), Rivaroxaban mean AUC was significantly increased by 2.3 fold compared to healthy volunteers. Unbound AUC was increased 2.6 fold. These patients also had reduced renal elimination of Rivaroxaban, similar to patients with moderate renal impairment. There are no data in patients with severe hepatic impairment.</p><p>The inhibition of factor Xa activity was increased by a factor of 2.6 in patients with moderate hepatic impairment as compared to healthy volunteers; prolongation of PT was similarly increased by a factor of 2.1. Patients with moderate hepatic impairment were more sensitive to Rivaroxaban resulting in a steeper PK/PD relationship between concentration and PT.</p><p>Rivaroxaban is contraindicated in patients with hepatic disease associated with coagulopathy and clinically relevant bleeding risk, including cirrhotic patients with Child Pugh B and C (see section 4.3).</p><p>&nbsp;</p><p>No clinical data is available in children with hepatic impairment.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>There was an increase in Rivaroxaban exposure correlated to decrease in renal function, as assessed via creatinine clearance measurements. In individuals with mild (creatinine clearance 50 - 80 ml/min), moderate (creatinine clearance 30 - 49 ml/min) and severe (creatinine clearance 15 - 29 ml/min) renal impairment, Rivaroxaban plasma concentrations (AUC) were increased 1.4, 1.5 and 1.6 fold respectively. Corresponding increases in pharmacodynamic effects were more pronounced. In</p><p>individuals with mild, moderate and severe renal impairment the overall inhibition of factor Xa activity was increased by a factor of 1.5, 1.9 and 2.0 respectively as compared to healthy volunteers; prolongation of PT was similarly increased by a factor of 1.3, 2.2 and 2.4 respectively. There are no data in patients with creatinine clearance &lt; 15 ml/min.</p><p>Due to the high plasma protein binding Rivaroxaban is not expected to be dialysable.</p><p>Use is not recommended in patients with creatinine clearance &lt; 15 ml/min. Rivaroxaban is to be used with caution in patients with creatinine clearance 15 - 29 ml/min (see section 4.4).</p><p>No clinical data is available in children 1 year or older with moderate or severe renal impairment (glomerular filtration rate &lt; 50 mL/min/1.73 m2).</p><p>&nbsp;</p><p><u>Pharmacokinetic data in patients</u></p><p>In patients receiving Rivaroxaban for treatment of acute DVT 20 mg once daily the geometric mean concentration (90% prediction interval) 2 - 4 h and about 24 h after dose (roughly representing maximum and minimum concentrations during the dose interval) was 215 (22 - 535) and 32 (6 - 239) mcg/l, respectively.</p><p>&nbsp;</p><p>In paediatric patients with acute VTE receiving body weight-adjusted rivaroxaban leading to an exposure similar to that in adult DVT patients receiving a 20 mg once daily dose, the geometric mean concentrations (90% interval) at sampling time intervals roughly representing maximum and minimum concentrations during the dose interval are summarised in Table 13.</p><p>Table 13: Summary statistics (geometric mean (90% interval)) of rivaroxaban steady state plasma concentrations (mcg/L) by dosing regimen and age</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Time intervals</p></td><td><p>&nbsp;</p></td><td style="width:109px"><p>&nbsp;</p></td><td style="width:40px"><p>&nbsp;</p></td><td style="width:126px"><p>&nbsp;</p></td><td style="width:35px"><p>&nbsp;</p></td><td style="width:118px"><p>&nbsp;</p></td><td style="width:40px"><p>&nbsp;</p></td><td style="width:133px"><p>&nbsp;</p></td></tr><tr><td><p>o.d.</p></td><td><p>N</p></td><td style="width:109px"><p>12 -&lt; 18 years</p></td><td style="width:40px"><p>N</p></td><td style="width:126px"><p>6 -&lt; 12 years</p></td><td style="width:35px"><p>&nbsp;</p></td><td style="width:118px"><p>&nbsp;</p></td><td style="width:40px"><p>&nbsp;</p></td><td style="width:133px"><p>&nbsp;</p></td></tr><tr><td><p>2.5-4h post</p></td><td><p>171</p></td><td style="width:109px"><p>241.5</p><p>(105-484)</p></td><td style="width:40px"><p>24</p></td><td style="width:126px"><p>229.7</p><p>(91.5-777)</p></td><td style="width:35px"><p>&nbsp;</p></td><td style="width:118px"><p>&nbsp;</p></td><td style="width:40px"><p>&nbsp;</p></td><td style="width:133px"><p>&nbsp;</p></td></tr><tr><td><p>20-24h post</p></td><td><p>151</p></td><td style="width:109px"><p>20.6</p><p>(5.69-66.5)</p></td><td style="width:40px"><p>24</p></td><td style="width:126px"><p>15.9</p><p>(3.42-45.5)</p></td><td style="width:35px"><p>&nbsp;</p></td><td style="width:118px"><p>&nbsp;</p></td><td style="width:40px"><p>&nbsp;</p></td><td style="width:133px"><p>&nbsp;</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0" align="left"><tbody><tr><td><p>b.i.d.</p></td><td><p>N</p></td><td><p>6 -&lt; 12 years</p></td><td><p>N</p></td><td><p>2 -&lt; 6 years</p></td><td><p>N</p></td><td><p>0.5 -&lt; 2 years</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>2.5-4h post</p></td><td><p>36</p></td><td><p>145.4</p><p>(46.0-343)</p></td><td><p>38</p></td><td><p>171.8</p><p>(70.7-438)</p></td><td><p>2</p></td><td><p>n.c.</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>10-16h post</p></td><td><p>33</p></td><td><p>26.0</p><p>(7.99-94.9)</p></td><td><p>37</p></td><td><p>22.2</p><p>(0.25-127)</p></td><td><p>3</p></td><td><p>10.7</p><p>(n.c.-n.c.)</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>t.i.d.</p></td><td><p>N</p></td><td><p>2 -&lt; 6 years</p></td><td><p>N</p></td><td><p>Birth -&lt; 2 years</p></td><td><p>N</p></td><td><p>0.5 -&lt; 2 years</p></td><td><p>N</p></td><td><p>Birth -&lt; 0.5 years</p></td></tr><tr><td><p>0.5-3h post</p></td><td><p>5</p></td><td><p>164.7</p><p>(108-283)</p></td><td><p>25</p></td><td><p>111.2</p><p>(22.9-320)</p></td><td><p>13</p></td><td><p>114.3</p><p>(22.9-346)</p></td><td><p>12</p></td><td><p>108.0</p><p>(19.2-320)</p></td></tr><tr><td><p>7-8h post</p></td><td><p>3</p></td><td><p>33.2</p><p>(18.7-99.7)</p></td><td><p>23</p></td><td><p>18.7</p><p>(10.1-36.5)</p></td><td><p>12</p></td><td><p>21.4</p><p>(10.5-65.6)</p></td><td><p>11</p></td><td><p>16.1</p><p>(1.03-33.6)</p></td></tr><tr><td colspan="9"><p>o.d. = once daily, b.i.d. = twice daily, t.i.d. three times daily, n.c. = not calculated</p><p>Values below lower limit of quantification (LLOQ) were substituted by 1/2 LLOQ for the calculation of statistics (LLOQ = 0.5 mcg/L).</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Pharmacokinetic/pharmacodynamic relationship</u></p><p>The pharmacokinetic/pharmacodynamic (PK/PD) relationship between Rivaroxaban plasma concentration and several PD endpoints (factor Xa inhibition, PT, aPTT, Heptest) has been evaluated after administration of a wide range of doses (5 - 30 mg twice a day). The relationship between Rivaroxaban concentration and factor Xa activity was best described by an Emax model. For PT, the linear intercept model generally described the data better. Depending on the different PT reagents used, the slope differed considerably. When Neoplastin PT was used, baseline PT was about 13 s and the slope was around 3 to 4 s/(100 mcg/l). The results of the PK/PD analyses in Phase II and III were consistent with the data established in healthy subjects.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>Safety and efficacy have not been established in the indication prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation for children and adolescents up to 18 years.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, single dose toxicity, phototoxicity, genotoxicity, carcinogenic potential and juvenile toxicity.</p><p>Effects observed in repeat-dose toxicity studies were mainly due to the exaggerated pharmacodynamic activity of Rivaroxaban. In rats, increased IgG and IgA plasma levels were seen at clinically relevant exposure levels.</p><p>In rats, no effects on male or female fertility were seen. Animal studies have shown reproductive toxicity related to the pharmacological mode of action of Rivaroxaban (e.g. haemorrhagic complications). Embryo-foetal toxicity (post-implantation loss, retarded/progressed ossification, hepatic multiple light coloured spots) and an increased incidence of common malformations as well as placental changes were observed at clinically relevant plasma concentrations. In the pre- and post-natal study in rats, reduced viability of the offspring was observed at doses that were toxic to the dams.</p><p>Rivaroxaban was tested in juvenile rats up to 3-month treatment duration starting at postnatal day 4 showing a non dose-related increase in periinsular haemorrhage. No evidence of target organ-specific toxicity was seen.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Microcrystalline cellulose, Croscarmellose sodium, Lactose monohydrate, Hypromellose 5 CPS, Sodium lauryl sulphate, Magnesium stearate, Opadry 04F540025 Pink, Opadry brown 04F565014, Opadry red 04F550002.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not Applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PVC/PVDC Blister</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p><p><u>Crushing of tablets</u></p><p>Rivaroxaban tablets may be crushed and suspended in 50 mL of water and administered via a nasogastric tube or gastric feeding tube after confirming gastric placement of the tube. Afterwards, the tube should be flushed with water. Since rivaroxaban absorption is dependent on the site of active substance release, administration of rivaroxaban distal to the stomach should be avoided, as this can result in reduced absorption and thereby, reduced active substance exposure. After the administration of a crushed rivaroxaban 15 mg or 20 mg tablet, the dose should then be immediately followed by enteral feeding.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sudair Pharma Company (SPC)
King Fahad road, Building 8006- 4th Floor Riyadh, Saudi Arabia
Tel: +966-11-920001432
Fax: +966-11-4668195
Email: info@sudairpharma.com
Mailing: P.O. Box 12363 Riyadh, Saudi Arabia

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                04/2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>